Feeds:
Posts
Comments

Archive for the ‘Regulated Clinical Trials: Design, Methods, Components and IRB related issues’ Category

 

Reporter: Aviva Lev-Ari, PhD, RN

Gordon H. Sun, M.D., Jeffrey D. Steinberg, Ph.D., and Reshma Jagsi, M.D., D.Phil.

N Engl J Med 2012; 367:687-690   August 23, 2012

Since the founding of the National Institutes of Health (NIH) and the National Science Foundation (NSF) more than six decades ago, the United States has maintained a preeminent position as a government sponsor of medical research. That primacy is being tested, however, by potent economic challenges. The NIH’s proposed budget for fiscal year 2013 would freeze baseline funding at 2012 levels, continuing a decade-long failure to keep pace with the rising costs of conducting medical research. Across-the-board cuts mandated by the Budget Control Act (BCA) of 2011 will also affect medical research, with the NIH, NSF, and other federal research sponsors sustaining budgetary reductions of about 8% next year.

Cuts to government-funded research will have adverse long-term effects on the health care system and the economy and may irreversibly compromise the work of laboratories long accustomed to receiving stable federal support. Moreover, many medical researchers could transfer their knowledge and resources abroad. In fact, five emerging Asian economic or technological powers — China, India, South Korea, Taiwan, and Singapore — already have medical research policies in place that are filling the void being created by ever more restrictive U.S. funding.

Several U.S.-based economists have justified increasing research budgets on the premise that medical discoveries have intrinsically high economic value. For example, Murphy and Topel have suggested that eliminating deaths related to heart disease had an estimated worth of $48 trillion, and a 1% reduction in cancer-related mortality could save $500 billion.1 Beyond these ambitious goals, however, are more practical arguments favoring support for medical research.

Local and regional economic benefits are one example. A June 2008 analysis by Families USA showed that during the NIH’s fiscal year 2007, nearly $23 billion in grants and contracts supported more than 350,000 jobs, with each dollar generating more than twice as much in direct state economic output in the form of goods and services. The NIH reported that almost 1 million Americans worked in for-profit medical businesses in 2008, earning $84 billion and generating $90 billion in goods and services, reinforcing the importance of preserving the U.S. position as a “knowledge hub” for medical research.2 Nevertheless, BCA cuts next year could result in at least 2500 fewer NIH grants, 33,000 fewer jobs, and a $4.5 billion loss in economic activity.3 Since the NIH’s budget represents less than 1% of overall federal spending, policymakers must reconsider whether shaving 8% from NIH outlays will have a noticeable positive effect on the national deficit or economy.

Fallout from funding cuts could include shifts in the U.S. medical research workforce. In 2000, the National Research Council noted both an overall shortage of medical researchers and inadequate funding for scientists working in the United States, which coincided with a decline in the number of funded NIH grant applications from 31% in fiscal year 2002 to 19% in 2010. This change is particularly critical for postdoctoral researchers, who represent the majority of the U.S. biomedical science workforce. According to the NSF, nearly half the 14,601 new postdoctoral-level researchers who were trained in the United States in 2009 were not U.S. citizens or permanent residents. If U.S. institutions are willing to devote money, training, and infrastructure to support talented, committed researchers, it would be an illogical waste of resources and poor long-term strategy to reduce federal grant mechanisms and wipe out potential job opportunities. Indeed, declining financial support may well encourage medical researchers to seek employment elsewhere.

As compared with the United States, China, India, South Korea, Taiwan, and Singapore have taken a sharply different view of medical research and have developed policies that foster medical research as an engine for economic growth and intellectual innovation (see tableMajor Government Agencies in Asia and Their Budgets for Medical Research.). Their national budgets are heavily based on scientific research and development, and funding is increasing, with budgetary targets ranging from 2 to 5% of their gross domestic products (GDPs). India’s funding goal for medical research alone is 2% of its GDP.

Increased funding for research infrastructure attracts scientists and organizations interested in high-quality research, including clinical trials. During the past two decades, increasing numbers of clinical trials have moved overseas, where benefits can include decreased costs of doing business, fewer administrative regulations, and greater enrichment of international relationships among researchers. The average annual rate of growth in clinical trials has been highest in China — 47% — while the number conducted in the United States has decreased by an average of 6.5% annually.4 In addition, the increased attention paid to Asia by private firms and other nongovernmental organizations has spurred rapid policy-level responses to concerns about the lack of informed consent, transparency, and other ethical issues, thus further strengthening the appeal of conducting research in the region.

Asian policies reflect a recognition of the extrinsic economic benefits of medical research. China and India have advocated for more government-funded medical research to improve health-related outcomes. China has espoused increased spending as part of achieving xiaokang, a Confucian term meaning a moderately prosperous society. In 2007, India inaugurated its Department of Health Research, which coordinates biomedical science and health-services research programs and translates their findings to address public health concerns. Since the signing of the Korean War Armistice Agreement in 1953, South Korea has leaned heavily on government-funded research to reduce poverty, allowing the country to gradually acquire advanced technologies and expertise. Medical research is part of at least two core technology areas in South Korea’s “577 Initiative”: medical technologies, such as neuroimaging, to address the needs of an aging population and research on issues pertaining to national safety and public health, such as infectious-disease preparedness and food safety.

National research and development programs have been a fundamental component of Taiwan’s economic policy for at least five decades. In 2005, the country began developing “intelligent medical care” — similar to earlier U.S. initiatives — which integrates medical information technology with quality-improvement measures. In Singapore, medical research and economic oversight are administratively linked. For example, the Biomedical Sciences Group of the Economic Development Board supports researchers financially and designs strategies that enhance Singapore’s status as a knowledge center, and the private firm Bio*One Capital invests directly in promising medical technologies.

The diverse strategies outlined above allow Asian countries to systematically recruit medical researchers from both home and abroad. China is particularly proactive in enticing Chinese-born, U.S.-educated researchers to return to their native country by offering generous financial and material incentives under its Knowledge Innovation Program. As the vice president of the Chinese Academy of Sciences stated more than a decade ago, modern “research and development is actually a war for more talented people.”5 In 2000, Singapore jump-started its Biomedical Sciences Initiative to attract medical researchers worldwide with a direct $2 billion investment, as well as with tax incentives for internal biotechnology start-ups and global pharmaceutical firms. In Singapore and India, English is the primary language for scientific communications, which alleviates concerns about language barriers.

For two decades, emerging Asian countries have been designing long-term strategies to reap the benefits of medical research. Meanwhile, the United States is relying on short-term solutions to support its medical research infrastructure, such as those offered by the Patient Protection and Affordable Care Act and the American Recovery and Reinvestment Act. Decreased investment in U.S. medical research could lead to long-term economic damage for the United States and the loss of its stature as a global leader in the field. Powerful incentives that can retain an elite biomedical-research workforce are necessary to strengthen the U.S. health care system and economy.

The views expressed in this article are those of the authors and do not necessarily reflect those of the Robert Wood Johnson Foundation, the Department of Veterans Affairs, or the Agency for Science, Technology, and Research.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

SOURCE INFORMATION

From the Robert Wood Johnson Foundation Clinical Scholars Program (G.H.S., R.J.), the Department of Otolaryngology (G.H.S.), and the Department of Radiation Oncology (R.J.), University of Michigan, and the Health Services Research and Development Service, VA Ann Arbor Healthcare System (G.H.S.) — both in Ann Arbor, MI; and the Singapore Bioimaging Consortium, Agency for Science, Technology, and Research, Singapore (J.D.S.).

http://www.nejm.org/doi/full/10.1056/NEJMp1206643?query=TOC

 

 

Read Full Post »

 

Reporter: Aviva Lev-Ari, PhD, RN

Will ‘gamifying’ drug R&D win more than Facebook fans for Boehringer?

By Tracy Staton, FiercePharma, August 22, 2012

Lots of computer games enlist players in quests to save the world. But how many would-be saviors are developing drugs? We can’t think of any–until now. Boehringer Ingelheim is on the verge of launching Syrum, a Facebook game of test tubes and titrations, not crossbows and assault rifles.

 “The health of the world is in your hands,” Boehringer’s director of digital, John Pugh, tells PSRK, in what could be a voice-over for a YouTube promo video for the game. “And you’re the only one who can save it.”

 Players have to solve a problem–e.g., a pandemic–via drug development, all the way from early discovery through clinical trials and launch. They can enlist help from Facebook friends, and advance in the game by checking into locations via the social network’s mobile app. “It wasn’t built with a view to being an educational platform,” Pugh says. “It’s very much a game which is meant to be engaging and entertaining … In the same way that Farmville doesn’t just appeal to people who like farms, Syrum isn’t just for people who like the pharmaceutical industry.”

But it was education that drew Pugh and his team into the project; as he points out for PSFK, the industry does a lot of it, whether that’s “educating” doctors about products, or teaching patients how to take their meds properly. Just because the game isn’t designed as an educational platform doesn’t mean it can’t educate, in a stealthy, backhanded way.

Syrum has been in development for two years. On Sept. 13, Boehringer will unveil a beta version at a London conference, aiming to get feedback from players for future iterations. “[T]he game will grow and evolve as more people play it,” Pugh says.

He also says Syrum is a “very unique offering from a highly regulated industry.” True. Whether it will remain unique depends, in part, on how Syrum actually fares. Will it attract a following? And if it does, will gamification of drug development actually benefit Boehringer’s business? Image? Relations with patients? Pharma’s social media advocates (and skeptics) will be watching.

John Pugh, Director of Digital for Boehringer Ingelheim, talks about driving innovation in his large organization with the forthcoming game Syrum – which he will launch at PSFK CONFERENCE LONDON on September 13.
 
 
 
 
By Tim Ryan on August 21, 2012.
  • John Pugh is the Director of Digital for Boehringer Ingelheim GmbH – a group of pharmaceutical companies that specialize in research and development for prescription medicine products. He spoke to PSFK recently about driving innovation in a large organization with his forthcoming game Syrum – which he will launch at PSFK CONFERENCE LONDON on September 13.

Your company has a new game, Syrum. What is it – and why is a pharmaceutical company like Boehringer Ingelheim involved in it?

What really sparked my interest in the potential of gaming is that a lot of what we do in pharma is around educating and teaching people; whether that’s teaching doctors about specific products, educating the general public and patients about diseases and healthy ways to live, or teaching people how to take their medication.

Gaming seems to be a useful way and effective way for us to do that. I basically began the journey to try and work out what I could do in gaming that wasn’t an arcade or platform based game — but was something a bit more immersive.

Syrum has been in development for at least two years. At the beginning, we called in lots of experts from different industries, different locations in countries, and with different skill sets. We had various leaders, from specialized futurologists to branding experts, from pharma people to gaming people, and even young entrepreneurs who’d made a million dollars by the age of 17.

We really worked together to create a vision of the future, and one of the strong things that came through was the influence of gaming and gamification.

After two years of hard work, the result is that we are about to launch Syrum, the pharmaceutical industry’s first social game.

syrum-boehringer-ingelheim

Can you tell us a little more about the gameplay in Syrum?

Syrum is a social game. The health of the world is in your hands, and you’re the only one who can save it. In each chapter, you have to solve a particular problem, which could be a disease or a pandemic that is sweeping the world. The player’s goal is to discover cures, create a stable drug, and then create a clinical trial so that you can launch the drug and cure the disease.

It’s a social game, because you can collaborate with friends or other people, and you can give them gifts, even headhunt their staff. As the game progresses, it gets more and more complicated.

syrum-boehringer-ingelheim-game

What do you think people will get out of it?

First, it’s a fun game. It wasn’t built with a view to being an educational platform or anything like that. It’s very much a game which is meant to be engaging and entertaining to play. In the same way that Farmville doesn’t just appeal to people who like farms, Syrum isn’t just for people who like the pharmaceutical industry. It’s for anyone to play.

It’s built on Facebook because that’s the world’s biggest gaming platform. What we really wanted to do was try to use a lot of the features of Facebook. For example we leverage Facebook Places, a service where people can check into locations. It’s really bridging that offline/online world. Places helps players market the products they make. Wherever the players check in through the Facebook mobile app, that data gets integrated into the game and you get rewarded accordingly.

syrum-boehringer-ingelheim-game

When will it be available?

September 13. We are taking a Silicon Valley approach, where we know we have got a really good game that’s stable but we’ll launch a beta version. We really want to make it so that we get lots of feedback from the people who are playing.

We’re offering rewards and prizes for people to give feedback so that we can really create the duration of the game, and develop it, and have more of a crowdsourced collaborative effort to develop the future stages of it, so the game will grow and evolve, as more people play it. This is a very unique offering from a highly regulated industry.

Can we finish by understanding your role within the organization – and how you drive change.

My job is anything which is connected to digital, so that includes apps, mobile, websites, gaming, crowdsourcing, and so forth. Our goal is to find applications for all of that. I bring to this company new ideas and I inspire them, educate them, cajole them, prod them to try new things, particularly in digital. I want BI to stretch out beyond the traditional marketing activities because in pharmaceuticals, and particularly at Boehringer, we’re still very traditional in what we do.

Thanks John!

Come see John talk about the launch of Syrum at PSFK CONFERENCE LONDON.

Syrum / @johnpugh / Boehringer Ingelheim

Click the banner below to purchase tickets and find additional information about this year’s event.

 

via PSFK: http://www.psfk.com/2012/08/pharma-social-game-psfk-london.html#ixzz24IgR5ZEm

http://www.psfk.com/2012/08/pharma-social-game-psfk-london.html

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA

BY BEN PAYNTER

 | 

AUGUST 20, 2012

After a Facebook PR meltdown two years ago, Sanofi has emerged as a social media leader with a robust community for diabetics. Here’s how they are writing #TheRules while the FDA catches up.

About This Series

#therules

Follow Fast Company’s roadmap to social media: surefire rules, data, and expert wisdom guaranteed to show why this market is completely unpredictable.READ MORE

The biggest challenge to treating patients with diabetes isn’t doling out medications, it’s making sure that people control their habits. Poor diet and lack of exercise generally create complications with the disease. To combat the problems, researchers in the diabetes division of Sanofi US took an unusual step for Big Pharma: they went social, jumping into online networking with a Facebook page, Twitter presence, and eventually three different engagement platforms.

“Treatment is an important aspect to blood sugar management, but it isn’t the only aspect,” says Laura Kolodjeski, Sanofi’s diabetes community manager, who has become the virtual face of the company. “There is a huge community of people already that live with diabetes and are connecting and sharing [online] to improve each other’s experience with the disease.”

 

Laura Kolodjeski

 

Sanofi now helps direct and police those interactions online. The company won’t release total visitor numbers, but it has about 4,000 followers on Facebook and another 4,000 on Twitter, all of whom are sharing links to broader content. And for better or worse that community is going to grow: About 8 percent of Americans or roughly 26 million people have diabetes, and the Centers for Disease Control predicts that as many as one third of us could have the disease by 2050.

But the social frontier is potentially prickly for Sanofi because the FDA has not yet written the rules about how pharmaceuticals are allowed to engage with potential customers and patients. The only guidelines came out in a December 2011 advisory statement declaring that while allowing virtual comments about things like off-label uses isn’t technically illegal, it’s shady territory; basically, pontificate at your own risk. “We are working on the area and it’s something we feel is important but we don’t have a specific timeline right now,” says Ernest Voyard, senior regulatory council at the FDA’s Office of Prescription Drug Promotion.

For Sanofi, drawing up their own social media strategy is also a defensive move: In 2010, the company’s cancer division suffered a PR nightmare after a patient, who claimed to have experienced permanent hair loss from one of their treatment drugs, posted complaints and photos on that group’s unmonitored Facebook page. John Mack, the editor of Pharma Marketing News, which tracks shifts in the pharmaceutical industry, says such hits are common anytime you try to pioneer a new space. “They’ve had some rough times, but they are learning a lot,” he adds.

Mack considers Sanofi a leader in the category, especially compared with the offerings from other companies. Diabetes juggernaut Novo Nordisk sponsors IndyCar driver Charlie Kimball to tweet @racewithinsulin, including when he injects with their products. And Pfizer’s ThinkScienceNow blog about developments and advances in research is wonky but not exactly customer friendly.

Sanofi has created a template they hope will eventually be deemed both acceptable to the FDA and cool for customers. The lessons they’ve learned in the last two years is a valuable addition to The Social Media Roadmap from our current issue.

Be Transparent

When she took over as social media director, one of the first things Kolodjeski did was post a bio with a photo of herself online at DiscussDiabetes to show who was moderating. She also disclosed that she wasn’t diabetic. Why? To build trust, the kind community members might not have for a faceless company run by mostly non-diabetics. The message: “If Laura is going to work every day to solve [issues] on our behalf, then others must be doing the same,” Kolodjeski says.

Rather than just explain the rules of their forums in a jargon-y “terms of use” agreement Kolodjeski also tapped Mark Gaydos, head of the company’s U.S. regulatory affairs for marketed products division, to do a Q&A about how the sites would function. For instance, anytime someone on the site mentions a product, they are technically promoting it, so there needs to be fair balance of potential benefits and risks explained alongside that per FDA guidelines. That means many posts get quarantined internally before posting, so the company can add additional links or annotations to more information. Sanofi only wants to allow discussion of FDA-approved uses for products–any mention of possible side-benefits or bonuses from tweaking the usual dose regimen is prohibited. To make sure everything meets these requirements, there is often a delay–sometimes up to 24 hours–between when users make comments and those comments become publicly visible.

To explain their business interest, Kolodjeski also interviewed Dennis Urbaniak, the head of the company’s U.S. diabetes business unit to explain what he calls the “360-degree partner” principle–an effort to inspire others to talk more and tap into that as a focus group for new ideas.

Let Users Shape Expansion

Sanofi launched their diabetes Facebook and Twitter handles in September 2010 mainly to offer news updates about the company and its offerings. On Facebook, any clinical questions were directed to a separate tab and often answered privately. On Twitter, medical concerns were covered via direct message. What was missing was a way to collect various poster’s lifestyle tips and inspirational messages all in one place. In January 2011, the company launched DiscussDiabetes to address that. They also run their own stories about successes, including highlights from A1C Champions, another company sponsored group of diabetics who have maintain the best or “A1C” target range of blood sugar levels.

By March of this year, the company took a look at the discussions that were being generated and realized that terms like A1C weren’t actually as universally understood as they once thought. To speed that learning curve, they launched Diabetepedia, which provides both simple definitions and links to other sites showing how terms are actually used in other online conversations.

The final step: After noticing how activity at Diabetepedia was spiking, Sanofi launched another site collecting lots of the content they were already linking to all in one place. The DX, which launched at the end of May, hosts daily dispatches by both Kolodjeski and stable of already popular bloggers (none of whom are paid directly) that include everything from a diabetes related comic strip to mommy blogs for parents with diabetic kids. “We really allowed the community to help identify what might be useful to them and where they might go next,” Kolodjeski says.

Give Users Even More Control

The medical glossary at Diabetepedia doesn’t just provide standard definitions to complex terminology, users are encouraged to submit their own entries, creating a sort of slang dictionary that makes complicated stuff more relatable to newcomers. For instance, glucoaster: that’s shorthand for “a rollercoaster of blood glucose levels, with blood sugar lows followed by blood sugar highs.” User contributions have helped the database grow by 30 percent to include more than 150 terms, all of which make it easier to users themselves to better convey thoughts in future postings.

The company also considers each media outpost an exclusive “channel,” which means there is lots of cross-posting of content from different platforms to make sure users who only tune into one place are being best served. “We certainly have people that overlap but for the most part people have selected which channel they feel represented by and communicate through,” Kolodjeski says. But at each stop, the company still tries to crowdsource bigger ideas.

This year, they asked users to help set priorities for the company’s annual Data Design Diabetes Innovation Challenge, which asks individuals, businesses and non-profits to create new initiatives for using big data to help others struggling with the disease. To help brainstorm for that, Sanofi’s social media troop was given the chance to visit a competition homepage and answer questions about what aspects of life with the disease might be consistently overlooked or ignored. Their answers were used to shape a final guideline for contestants that solutions must address the overall wellness and family life of patients, not just symptom mediation. The winner: a program created by the n4a Diabetes Care Center that matches people with certain cost or risk profiles directly to the services they might need to slow the progression or expense of the disease. Mood problems can be addressed by better disease management, hopefully cutting into the 18 percent of all diabetics who require hospitalization each year.

After realizing just how open users are to sharing and connecting, Sanofi also launched their own new product, the iBGStar, a personal blood glucose monitor that plugs directly into an iPhone or iPod Touch with an app that saves data and maps correlations between blood sugar levels and meal times, carb and sugar intake, and physical activity. Users can share results with their family or email them to health care providers. But the product, which hit the market in May 2012, wasn’t just inspired by early community actions; ensuing reviews and comments in their own forums will help refine future updates. “It’s a big hit with the online community,” Kolodjeski says. “It’s also given us a great opportunity to prove back to them that if we hear someone comment about something, we have the ability to engage in a public manner.”

Correction: An earlier version of this article said that iBGStar came on the market in 2011, it was released in May 2012.

http://www.fastcompany.com/3000457/how-sanofi-writing-social-media-rules-big-pharma-without-running-afoul-fda

Lilly to develop company-wide social media strategy

11 Jul 2012

 
Nearly two years after launching its first major foray into the world of social media in the shape of its LillyPad corporate blog, Eli Lilly is developing a company-wide social media strategy.

Lilly has so far had strict rules about who can use social media on behalf of the company, authorising just a handful of people in corporate communications and government affairs, but now wants to empower other departments to do so.

“There are a lot of parts of the company that are getting interested in social media so I’m working on a strategy that will keep these aligned with one another,” Lilly’s director of corporate communications Greg Kueterman told SMI’s Social Media in the Pharmaceutical Industry conference on Monday.

“We don’t want to have eight different social media platforms that all look and sound very different from one another. So we’re going to try and do something where they all have their own identity but are still consistent within the company.”

Kueterman acknowledged LillyPad, launched September 2010, and the company’s Campaign For Modern Medicines, a US health policy initiative Lilly founded last year that uses Twitter, Facebook and YouTube, were set up “before we had a full blown strategy”.

“But sometimes that is important,” he said. “Because you have to know what you have, before you can make it even bigger.”

The company’s Clinical Open Innovation team, a group working to improve the drug development process, also began using social media earlier this year, with a blog and Twitter account.

The next stage for Lilly will be to continue its expansion of LillyPad (as previewed herein March), following the launch in May of a Canadian version of the corporate blog.

“We’ve started to go global with LillyPad and we’re working with a number of our affiliates to do this. Lilly Canada has been the first one out of the box to do that and they’re off to a nice start,” Kueterman said.

Discussions are underway with the company’s European affiliates in the UK and Belgium along with its operations in Mexico. “Hopefully some of those are going to be launching this year, although we don’t have firm dates yet,” Kueterman said.

“We’re excited that this is a programme that’s going to start picking up momentum. Looking ahead there are still things that we can do much better. I’m never really satisfied with the way things are going with LillyPad – I’m happy, because I think we’re doing things the right way, but I also believe that we can be even more proactive than we are.”

• Links to Lilly’s social media presences can be found in the Pharma Social Media Directory‘s blogsTwitterFacebook and YouTube sections 

http://www.pmlive.com/digital_intelligence_blog/archive/2012/jul_2012/lilly_to_develop_company-wide_social_media_strategy

What Else Can We (Really) Do?

by Greg Kueterman 07/10/12 


On Monday, I had the pleasure of presenting Lilly’s social media history and strategy at a conference in London. The history part was easy: LillyPad — our first major platform — has been around for 22 months. We’re not experiencing the Terrible Twos just yet, but we’ve still got plenty to learn.

The London audience — consisting of European and U.S. communicators and marketing experts at the Social Media for Pharmaceutical Industry conference. — warmly embraced our strategy of addressing issues such as public policy and medical innovation. And the reception was not unusual. Over the last two years, we’ve talked LillyPad in live settings from London to New York to Indianapolis to San Francisco — and our peers typically offer two thumbs up for the good work.

For that, we are grateful. But it’s a good reminder about a couple questions we need to ask more often:

What else can we be doing? What else should we be doing?

As our loyal readers, you know what we offer — and you know what you need to become more informed. We would love to hear more from you: the good, the bad, and the ugly. We’re always looking to enhance LillyPad, and we’ve taken a lot of steps in recent months to do so (more video, more guest blogs, and — we think — clearer, more conversational writing). And while we will remain a non-product communications vehicle, we’re open to any and all ideas that make your LillyPad experience even better.

From London (where I’ve seen more rain in three days than my backyard has seen in two months) thanks for reading!

http://lillypad.lilly.com/entry.php?id=1736

 

 

Read Full Post »

New Drug-Eluting Stent Works Well in STEMI

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 8/8/2013

Meta-analysis makes case for drug-eluting stents in STEMI

AUGUST 7, 2013 

New York, NY – Newer-generation drug-eluting stents, particularly the everolimus-eluting stent (Xience V, Abbot; Promus, Boston Scientific), significantly reduce the risk of target vessel revascularization (TVR) in patients with ST-segment-elevation MI (STEMI) without increasing the risk of adverse safety outcomes, including rates of stent thrombosis, when compared with bare-metal stents [1].

These are the principal findings of a new meta-analysis of 28 randomized, controlled clinical trials involving more than 34 000 patient-years of follow-up.

Published online August 6, 2013 in Circulation: Cardiovascular Interventions, the analysis showed that compared with the sirolimus-eluting stent (Cypher, Cordis), the paclitaxel-eluting stent (Taxus, Boston Scientific), and bare-metal stents, the use of an everolimus-eluting stent reduced the relative risk of stent thrombosis 62%, 61%, and 58%, respectively.

“I would make a strong argument to say that the current guidelines should change,” lead investigator Dr Sripal Bangalore (New York University School of Medicine) told heartwire. “The reduction in TVR is not surprising. We know that drug-eluting stents compared with bare-metal stents reduce TVR, but the biggest thing we were able show was that stent thrombosis is also reduced when compared with a bare-metal stent, as well as compared with first-generation drug-eluting stents.”

The current American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) clinical guidelines state that drug-eluting-stent implantation is a class IIa indication in STEMI patients. The recommendations are based on concerns about an increased risk of stent thrombosis with the drug-eluting stents compared with their bare-metal counterparts. Bangalore said concerns have also been raised about the risk of stent thrombosis beyond one year with the first-generation drug-eluting stents, a time point when dual antiplatelet therapy is stopped.

The newer-generation drug-eluting stents, however, have been shown in various studies to be as safe asbare-metal stents in the STEMI setting. For this reason, they conducted a meta-analysis of randomized, controlled trials comparing the sirolimus-, paclitaxel-, everolimus-, and zotarolimus-eluting stents against each other and against bare-metal stents.

When compared with bare-metal stents, the sirolimus-, paclitaxel-, and everolimus-eluting stent reduced the relative risk of TVR by 53%, 31%, and 57%, respectively. The sirolimus-eluting stent was significantly more effective than the paclitaxel-eluting stent at reducing TVR, as was the everolimus-eluting stent. Overall, there was a 67% probability that the Endeavor Resolute zotarolimus-eluting stent (Medtronic) had the lowest risk of TVR, although the data are based on just one trial with 281 patients, note the investigators.

Median rate of efficacy and definite/probable stent thrombosis

Stent type TVR rate (per 1000 patient-years of follow-up) Definite/probable stent thrombosis (per 1000 patient-years of follow-up)
Bare metal 64.00 16.60
Sirolimus 28.93 15.75
Paclitaxel 44.38 18.46
Everolimus 26.55 6.54
Zotarolimus 59.01 11.41
Zotarolimus (Resolute) 14.76 NA*

 

*For stent thrombosis, there were no available data on the Resolute stent

When compared with bare-metal stents, the everolimus-eluting stent reduced the risk of any stent thrombosis by 58%. The Xience stent was also associated with a statistically significant 62% and 61% reduction in the risk of stent thrombosis compared with the first-generation Cypher and Taxus stents.

Bangalore said that a previous patient-level analysis conducted by Dr Giuseppe De Luca (Ospedale Maggiore della Carità, Novara, Italy), reported by heartwire at that time, showed there was a significant 50% increase in the risk of late (more than one year) reinfarction with drug-eluting stents and an almost doubling of very late stent thrombosis with first-generation stents. In this newest meta-analysis, however, the researchers did not observe a similarly increased risk of very late stent thrombosis with the everolimus-eluting stent.

“Based on the totality of data, I would say that it’s time the guidelines make drug-eluting stents and especially the everolimus-eluting stent a class I indication in STEMI patients who can take dual antiplatelet therapy,” said Bangalore.

Source

  1. Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F. Outcomes with various drug-eluting or bare-metal stents in patients with ST-segment elevation myocardial infarctionCirc Cardiovasc Interv 2013; DOI:10.1161/CIRCINTERVENTIONS.113.000415. Available at: http://circinterventions.ahajournals.org.

 

New Drug-Eluting Stent Works Well in STEMI

By Michael Smith, North American Correspondent, MedPage Today

Published: August 21, 2012

Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

 Watch Video

 A new-generation biodegradable drug-eluting stent had a lower rate of major cardiac events than similar bare-metal devices, researchers reported.

In a randomized trial, patients with ST-segment elevation myocardial infarction (STEMI) needed fewer revascularization procedures and had a lower risk of a new heart attack in the target blood vessel, according to Stephan Windecker, MD, of Bern University Hospital in Bern, Switzerland, and colleagues.

On the other hand, rates of cardiac death were not significantly different, Windecker and colleagues reported in the Aug. 22/29 issue of the Journal of the American Medical Association.

Drug-eluting stents have been shown to reduce the need for repeat revascularization, compared with bare-metal stents, but at the cost of delayed healing, chronic inflammation, and late stent thrombosis, the researchers noted.

The long-term effects result from the persistence of the polymer, Windecker and colleagues noted — something that might be avoided by using a biodegradable polymer.

The biodegradable BioMatrix Flex stent, which delivers the immunosuppressant drug biolimus, was non-inferior in a 4-year trial to the sirolimus-eluting Cypher stent, which does not break down over time.

But it had not been tested against bare-metal stents. To help fill the gap, Windecker and colleagues studied 1-year outcomes in 1,161 STEMI patients randomly assigned to get either the biolimus-eluting biodegradable stent or a similar bare-metal device.

The primary endpoint of the trial was the 1-year rate of major adverse cardiac events — a composite of cardiac death, target vessel-related re-infarction, and ischemia-driven target-lesion revascularization.

Windecker and colleagues found that 24 patients (4.3%) with biodegradable stents had a major adverse cardiac event at 1 year, compared with 49 (8.7%) who were given the bare-metal devices (HR 0.49, 95% CI 0.30 to 0.80, P=0.004).

The difference was driven by a lower risk of two of the elements of the combined endpoint: target vessel-related reinfarction and ischemia-driven target-lesion revascularization. Specifically:

  • Three patients getting the biodegradable stent (0.5%) had a re-infarction related to the target vessel, compared with 15 (2.7%) of those with bare-metal devices (HR 0.20, 95% CI 0.06 to 0.69, P=0.01).
  • Nine patients (1.6%) with biodegradable stents and 32 (5.7%) with bare-metal devices needed target-lesion revascularization (HR 0.28, 95% CI 0.13 to 0.59, P<0.001).
  • Rates of cardiac death were numerically lower, but not significantly so, in the biodegradable stent patients — 16 deaths, or 2.9%, versus 20, or 3.5%.

Definite stent thrombosis occurred in five patients treated with the drug-eluting stents and 12 patients with bare-metal stents, but the difference did not reach significance.

The findings should be “reassuring” to both doctors and patients, Windecker said in a video released by the journal.

The study is “a well-done trial with convincing results regarding its primary end point,” commented Salvatore Cassese, MD, and Adnan Kastrati, MD, both of the Technische Universitat in Munich, Germany.

But, in an accompanying editorial, they argued that it still may not settle the question of long-term complications.

Despite “positive signals,” they wrote, the study has “neither the required sample size nor the sufficient length of follow-up to provide the definitive answer about the long-term safety” of the new biodegradable drug-eluting stents.

The researchers cautioned that the biodegradable drug-eluting stent is not yet approved in the U.S., although European authorities have given it the nod.

They also noted that the study, while demonstrating superiority on the overall endpoint, did not have sufficient statistical power to address the individual components definitively.

The study had support from the Swiss National Science Foundation and Biosensors Europe SA. Windecker reported financial links through his institution with Abbott, Boston Scientific, Biosensors, Biotronik, Cordis, Medtronic, and St. Jude Medical.

The editorial authors reported support from the European Commission. Kastrati reported holding a patent related to polymer-free sirolimus and probucol coating, as well as financial links with Abbott, Biosensors, Cordis, and Medtronic.

From the American Heart Association:

Related Articles in Heart.org

Related links

Read Full Post »

 

Author: Larry Bernstein, MD

 

Creagh-BrownBC, Griffiths MJD, Evans TW. “Bench-to-bedside review: Inhaled nitric oxide therapy in adults”. Crit Care.  2009;  13(3): 221. Published online 2009 May 29. doi:  10.1186/cc7734. PMCID: PMC2717403.

This article is modified from a review series on Gaseous mediators, edited by Peter Radermacher.  Other articles in the series can be found online athttp://ccforum.com/series/gaseous_mediators

 

Part I.   Basic and downstream effects of inhaled NO

Inhaled nitric oxide (NO), a mediator of vascular tone produces pulmonary vasodilatation with low pulmonary vascular resistance. The route of administration delivers NO selectively improving oxygenation. Developments in our understanding of the cellular and molecular actions of NO may help to explain the results of randomised controlled trials of inhaled NO.

Introduction

Nitric oxide (NO), a determinant of local blood flow is formed by the action of NO synthase (NOS) on L-arginine in the presence of molecular oxygen. Inhaled NO results in preferential pulmonary vasodilatation it lowers pulmonary vascular resistance (PVR), correcting hypoxic pulmonary vasoconstriction (HPV). However, in the therapeutic use of gaseous NO to patients with acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and related conditions, evidence of a benefit is disappointing.

Administration of inhaled nitric oxide to adults

The licensed indication of inhaled NO is restricted to persistent pulmonary hypertension in neonates. Pharma-ceutical NO is costly, and raises concerns over potential adverse effects of NO. Therefore, an advisory board under the auspices of the European Society of Intensive Care Medicine and the European Association of Cardiothoracic Anaesthesiologists published recommendations in 2005 [1]. The sponsor had no authorship or editorial control over the content of the meetings or any subsequent publication.

The NO is administered as a NO/nitrogen mixture to the tubing of ventilated patients, and the NO and NO2 concen-trations are monitored, with methemoglobin levels measured regularly. Even though rapid withdrawal induces rebound pulmonary hypertension, it is avoided by gradual withdrawal [2]. There is variation in vasodilatory response to administered NO between patients [2] and in the same patient, and there is a leftward shift in the dose-response curve with use. Toxicity and loss of the therapeutic effect is a risk of excessive NO administration [3]. A survey of 54 intensive care units in the UK as well as results of a European survey revealed that the most common usage was in treating ARDS, followed by pulmonary hypertension [4], [5]. The only use of therapeutic inhaled NO usage in US adult patients reported from a single medical site (2000 to 2003) reveals that the most common application was in the treatment of RVF in patients after cardiac surgery and then, in surgical and medical patients for refractory hypoxemia[6].

Inhaled nitric oxide in acute lung injury and acute respiratory distress syndrome

ALI and ARDS are characterised by hypoxemia despite high inspired oxygen (PaO2/FiO[arterial partial pressure of oxygen/fraction of inspired oxygen] ratios of less than 300 mm Hg [40 kPa] and less than 200 mm Hg [27 kPa], respectively) in the context of evidence of pulmonary edema, and the absence of left atrial hypertension suggestive of a cardiogenic mechanism [7]. Pathologically, there is alveolar inflammation and injury leading to increased pulmonary capillary permeability and a serous alveolar fluid with inflammatory infiltrate. This is manifest clinically as hypoxemia, inadequate alveolar perfusion, venous-arterial shunting, atelectasis, and reduced compliance.

Since 1993, when the first investigation on the effects of NO on adult patients with ARDS was published [8], there have been several randomised controlled trials (RCTs) examining the effect in ALI/ARDS  ​(Table 1). The first systematic review and meta-analysis [9] found no beneficial effect on mortality or ventilator-free days. A more recent meta-analysis that considered 12 RCTs with a total of 1,237 patients [10] concluded: [1] no mortality benefit, [2] improved oxygenation at 24 hours (13% improvement in PaO2/FiOratio) at the cost of increased risk of renal dysfunction (relative risk 1.50, 95% confidence interval 1.11 to 2.02). Based on a trend to increased mortality in patients receiving NO, the authors suggested that it not be used in ALI/ARDS.  Why the NO fails to improve patient outcomes requires clarifying the effects of inhaled NO that occur outside the pulmonary vasculature.

From:

Published online 2009 May 29. doi: 10.1186/cc7734

Table 1

Studies of inhaled nitric oxide in adult patients with acute lung injury/acute respiratory distress syndrome

The biological action of inhaled nitric oxide

NO was first identified as an endothelium-derived growth factor (EDGF) and an important determinant of local blood flow [11]. NO reacts very rapidly with free radicals, certain amino acids, and transition metal ions. The action of NOS on the semi-essential amino acid L-arginine in the presence of molecular oxygen and its identity with EDGF was the basis for the Nobel discovery of Furthgott and others [12]. Three isoforms of NO are: neuronal NOS, inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3). Calcium-independent iNOS generates higher concentrations of NO [13] than the other isoforms and its role has been implicated in the pathogenesis septic shock.

Exogenous NO is administered by controlled inhalation or through intravenous administration of NO donors. It was thought to have no remote or non-pulmonary effects. The effect NO has on circulating targets is shown. (Figure 1).

From:

Published online 2009 May 29. doi: 10.1186/cc7734

Figure 1

New paradigm of inhaled nitric oxide (NO) action. Figure 1 illustrates the interactions between inhaled NO and the contents of the pulmonary capillaries. Although NO was considered to be inactivated by hemoglobin (Hb), proteins including Hb and albumin contain reduced sulphur (thiol) groups that react reversibly with NO causing it to lose its vasodilating properties. A stable derivate, in the presence of oxyhemoglobin, is formed by a reaction resulting in nitrosylation of a cysteine residue of the β subunit of Hb.  The binding of NO to the heme iron predominates in the deoxygenated state [14]. If circulating erythrocytes store and release NO peripherally in areas of low oxygen tension, this augments peripheral blood flow and oxygen delivery via decreased systemic vascular resistance [15]. Thus, NO can act as an autocrine or paracrine mediator but when stabilised may exert endocrine influences [16]. In addition to de novo synthesis, supposedly inert anions nitrate (NO3) and nitrite (NO2) can be recycled to form NO, and nitrite might mediate extra-pulmonary effects of inhaled NO [17]. In the hypoxic state, NOS cannot produce NO and deoxy-hemoglobin catalyses NO release from nitrite, potentially providing a hypoxia-specific vasodilatory effect. Given that effects of inhaled NO are mediated in part by S-nitrolysation of circulating proteins, therapies aiming at directly increasing S-nitrosothiols have been developed.

Introduce another effect. When inhaled with high concentrations of oxygen, gaseous NO slowly forms the toxic product NO2, but other potential reactions include nitration (addition of NO2+), nitrosation (addition of NO+), or nitrosylation (addition of NO), and reaction with reactive oxygen species such as superoxide to form reactive nitrogen species (RNS) such as peroxynitrite (ONOO). These reactions of NO, potentially cytotoxic NO2 , and covalent nitration of tyrosine in proteins by RNS lead to measures of oxidative stress.

In a small observational study, inhaled ethyl nitrite safely reduced PVR without systemic side effects in persistent pulmonary hypertension of the newborn [18]. In animal models, pulmonary vasodilatation was maximal in hypoxia and had prolonged duration of action after cessation of administration [19].

References

  1. Germann P, Braschi A, Della Rocca G, Dinh-Xuan AT, et al. Inhaled nitric oxide therapy in adults: European expert recommendations.  Intensive Care Med. 2005;31:1029–1041. [PubMed]
  2. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med. 2005;353:2683–2695. [PubMed]
  3. Gerlach H, Keh D, Semmerow A, Busch T, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 2003;167:1008–1015. [PubMed]
  4. Cuthbertson BH, Stott S, Webster NR. Use of inhaled nitric oxide in British intensive therapy units. Br J Anaesth. 1997;78:696–700.[PubMed]
  5. Beloucif S. A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine. Intensive Care Med. 1998;24:864–877.[PubMed]
  6. George I, Xydas S, Topkara VK, Ferdinando C, et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg. 2006;82:2161–2169. [PubMed]
  7. Bernard GR, Artigas A, Brigham KL, Carlet J,et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824. [PubMed]
  8. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med.1993;328:399–405. [PubMed]
  9. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg. 2003;97:989–998. [PubMed]
  10. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis.  BMJ. 2007;334:779.[PMC free article] [PubMed]
  11. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.  Nature. 1987;327:524–526. [PubMed]
  12. Nitric Oxide: The Nobel Prize in Physiology or Medicine 1998 Robert F. Furchgott, Louis J. Ignarro, Ferid Murad. Leaders in Pharmacutical Intelligence.  A blog specializing in Pharmaceutical Intelligence and Analytics
  13. McCarthy HO, Coulter JA, Robson T, Hirst DG. Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J Pharm Pharmacol. 2008;60:999–1017. [PubMed]
  14. Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature.   Arterioscler Thromb Vasc Biol. 2007;27:1877–1885. [PubMed]
  15. McMahon TJ, Doctor A. Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc Am Thorac Soc. 2006;3:153–160. [PMC free article] [PubMed]
  16. Cokic VP, Schechter AN. Effects of nitric oxide on red blood cell development and phenotype. Curr Top Dev Biol. 2008;82:169–215. [PubMed]
  17. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7:156–167. [PubMed]
  18. Moya MP, Gow AJ, Califf RM, Goldberg RN, Stamler JS. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet  2002; 360:141–143. [PubMed]

Creagh-BrownBC, Griffiths MJD, Evans TW. “Bench-to-bedside review: Inhaled nitric oxide therapy in adults”. Crit Care.  2009;  13(3): 221. Published online 2009 May 29. doi:  10.1186/cc7734. PMCID: PMC2717403.

This article is modified from a review series on Gaseous mediators, edited by Peter Radermacher.

Other articles in the series can be found online athttp://ccforum.com/series/gaseous_mediators

Part II. Application of inhaled NO and circulatory effects

Cardiovascular effects

NO activates soluble guanylyl cyclase by binding to its heme group to form cyclic guanosine 3’5′-monophosphate (cGMP)   activating a protein kinase. Consequently, myosin sensitivity to calcium-induced contraction is reduced lowering the intracellular calcium concentration as a result of activating calcium-sensitive potassium channels and inhibiting release of calcium. The smooth muscle cell (SMC) relaxation with decrease in pulmonary vascular resistance (PVR) and decreased RV after load could improve cardiac output. However, left ventricular impairment associated with decrease in PVR allows increased RV output to a greater extent than the left ventricle can accommodate and the increase in left atrial pressure reinforces pulmonary edema.

Inhaled NO augments the normal physiological mechanism of hypoxic pulmonary ventilation (HPV) and improves systemic oxygenation ​(Figure 2). The effects of inhaled NO on systemic oxygenation are limited. Experiments show that intravenously administered vasodilators counteract HPV [3]. However, the non-pulmonary effects of inhaled NO include increased renal and hepatic blood flow and oxygenation [14].

From:

Published online 2009 May 29. doi: 10.1186/cc7734

Figure 2

Hypoxic pulmonary vasoconstriction (HPV).       (a) Normal ventilation-perfusion (VQ) matching. (b) HPV results in VQ matching despite variations in ventilation and gas exchange between lung units. (c) Inhaled nitric oxide (NO) augmenting VQ matching by vasodilating.

Non-cardiovascular effects relevant to lung injury

Neutrophils are important cellular mediators of ALI. Limiting neutrophil production of oxidative species and proteolysis reduces lung injury. In neonates, prolonged administration of NO diminished neutrophil-mediated oxidative stress [19]. Neutrophil deformability and CD18 expression were reduced in animal models [20] accomp-anied by decreases in adhesion and migration [21]. These changes limit damage to the alveolar-capillary membrane and the accumulation of protein-rich fluid within the alveoli. Platelet activation and aggregation, intra-alveolar thrombi, contribute to ALI. Inhaled NO attenuates the procoagulant activity in animal models of ALI [22] and a similar effect is seen in patients with ALI [23], but also in healthy volunteers [23,24]. In patients with ALI, decreased surfactant activity in the alveoli and noncompliance, as we recall is hyaline membrane disease accompanied by impaired pulmonary function [25].  The deleterious effects of the NO damages the alveolar wall with loss of surfactant by reactions with RNS [26]. Finally, prolonged exposure to NO in experimental models impairs cellular respiration [27].

The failure of inhaled NO to improve outcome in ALI/ARDS is therefore potentially due to several factors. First, patients with ALI/ARDS die of multi-organ failure, as the actions of NO are not expected to improve the outcome of multi-organ failure, which is a cytokine driven process leading to circulatory collapse. Indeed, the expected beneficial effect of inhaled NO is abrogated by detrimental downstream systemic effects discussed. Second, ALI/ARDS is a heterogeneous condition with diverse causes. Finally, using inhaled NO without frequent dose titration risks unwanted systemic effects without the expected benefits.

Other clinical uses of inhaled nitric oxide

Pulmonary hypertension and acute right ventricular failure

RVF may develop when there is abnormally elevated PVR and/or impaired RV perfusion.  ​Table 2 lists common causes of acute RVF. The RV responds poorly to inotropic agents but is exquisitely sensitive to after load reduction.

From:

Published online 2009 May 29. doi: 10.1186/cc7734

Table 2

Reducing PVR will have beneficial effects on cardiac output and therefore oxygen delivery. In the context of high RV afterload with low systemic pressures or when there is a limitation of flow within the right coronary artery [28], RV failure triggers a backward failure of venous return, as diagrammatically represented in  ​Figure 3.

From:

Published online 2009 May 29. doi: 10.1186/cc7734

Figure 3

Pathophysiology of right ventricular failure. CO, cardiac output; LV, left ventricle; PAP, pulmonary artery pressure; PVR, pulmonary vascular resistance; RV, right ventricle.

Inhaled NO is used when RV failure complicates cardiac surgery, as cardiopulmonary bypass per se causes diminished endogenous NO production [29]. There is marked variation in response to inhaled NO between patients [30] and in the same patient over time. After prolonged use, there is a leftward shift in the dose-response curve.  The risk of excessive NO administration is associated with toxicity and loss of the therapeutic effect without regular titration against a therapeutic goal [31].  Further, cardiac transplantation may be complicated by pulmonary hypertension and RVF that are improved with NO [32]. Early ischemia-reperfusion injury after lung transplantation manifests clinically as pulmonary edema and is a cause of significant morbidity and mortality [33,34]. Although NO has been administered in this circumstance [35], it hasn’t prevented ischemia-reperfusion injury in clinical lung transplantation [36]. Inhaled NO has been used successfully in patients with cardiogenic shock and RVF associated with acute myocardial infarction [37,38,46], and in patients with acute RVF following acute pulmonary venous thrombo-emboli [39, 47].  An explanation is needed in view of the downstream effects of systemic vasoconstriction and MOF previously identified. No systematic evaluation of inhaled NO and its effect on clinical outcome has been conducted in these conditions.

Acute chest crises of sickle cell disease

Acute chest crises are the second most common cause of hospital admission in patients with sickle cell disease (SCD) and are responsible for 25% of all related deaths [40]. Acute chest crises are manifest by fever, respiratory symptoms or chest pain, and new pulmonary infiltrate on chest  x-ray. The major contributory factors are related to vaso-occlusion. Hemolysis of sickled erythrocytes releasing Hb into the circulation generates reactive oxygen species and reacts with NO [41]. In SCD, the free Hb depletes NO. In addition arginase 1 is released, depleting the arginine needed for NO production, [42]. While secondary PVH is common in adults with SCD the physiological rationale for the use of inhaled NO needs to be considered, except for the complication just referred to. Thus far, iNO has failed to demonstrate either persistent improvements in physiology or beneficial effects on any accepted measure of outcome in clinical trials (other than its licensed indication in neonates). Therefore, inhaled NO is usually reserved for refractory hypoxemia.

Potential problems in designing and conducting RCTs in the efficacy of inhaled NO are numerous. Blinded trials will be difficult to conduct as the effects of inhaled NO are immediately apparent. Recruitment is limited as there is little time for consent/assent or randomization. Finally, industry funding might cast doubt on the independence of the trial results.

Inhaled NO is an unproved tool in the intensivist’s armamentarium of rescue therapies for refractory hypoxemia even though it has an established role in managing complications of cardiac surgery and in heart/lung transplantation. The current place for inhaled NO in the management of ALI/ARDS, acute sickle chest crisis, acute RV failure, and acute pulmonary embolism is a rescue therapy.

Abbreviations

ALI: acute lung injury; ARDS: acute respiratory distress syndrome; Hb: haemoglobin; HPV: hypoxic pulmonary vasoconstriction; iNO: inhaled nitric oxide; iNOS: inducible nitric oxide synthase; NO: nitric oxide; NO2: nitrogen dioxide; NOS: nitric oxide synthase; PaO2/FiO2: arterial partial pressure of oxygen/fraction of inspired oxygen; PVR: pulmonary vascular resistance; RCT: randomised controlled trial; RNS: reactive nitrogen species; RV: right ventricle; RVF: right ventricular failure; SCD: sickle cell disease; SMC: smooth muscle cell.

  1. Hunter CJ. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med 2004; 10:1122–1127. [PubMed]
  2. Gessler P, Nebe T, Birle A, Mueller W, Kachel W. A new side effect of inhaled nitric oxide in neonates and infants with pulmonary hypertension: functional impairment of the neutrophil respiratory burst. Intensive Care Med 1996; 22:252–258. [PubMed]
  3. Sato Y, Walley KR, Klut ME, English D, D’yachkova Y, et al. Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression. Am J Respir Crit Care Med 1999; 159:1469–1476. [PubMed]
  4. Bloomfield GL, Holloway S, Ridings PC, Fisher BJ, et al. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med 1997; 25:584–593. [PubMed]
  5. Kermarrec N, Zunic P, Beloucif S, Benessiano J, et al. Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxic lung injury. Role of cyclic guanosine 5′-monophosphate. Am J Respir Crit Care Med. 1998;158:833–839.[PubMed]
  6. Gries A, Bode C, Peter K, Herr A, Böhrer H, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation. 1998;97:1481–1487. [PubMed]
  7. Gries A, Herr A, Motsch J, Holzmann A, Weimann J, et al. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers. Thromb Hemost 2000; 83:309–315. [PubMed]
  8. Cheng IW, Ware LB, Greene KE, Nuckton TJ, et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med 2003; 31:20–27. [PubMed]
  9. Robbins CG, Davis JM, Merritt TA, Amirkhanian JD et al. Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation. Am J Physiol 1995; 269(4 Pt 1):L545–550. [PubMed]
  10. Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitro-sylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 1998; 95:7631–7636. [PMC free article] [PubMed]
  11. Vlahakes GJ. Right ventricular failure following cardiac surgery. Coron Artery Dis 2005; 16:27–30. [PubMed]
  12. Morita K, Ihnken K, Buckberg GD, Sherman MP, Ignarro LJ. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann Thorac Surg 1996; 61:1775–1780.[PubMed]
  13. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993; 88 (5 Pt 1):2128–2138. [PubMed]
  14. Solina A, Papp D, Ginsberg S, Krause T, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000; 14:12–17. [PubMed]
  15. Ardehali A, Hughes K, Sadeghi A, Esmailian F, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001; 72:638–641. [PubMed]
  16. King RC, Binns OA, Rodriguez F, Kanithanon RC, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69:1681–1685. [PubMed]
  17. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167:490–511. [PubMed]
  18. Kemming GI, Merkel MJ, Schallerer A, Habler OP, et al. Inhaled nitric oxide (NO) for the treatment of early allograft failure after lung transplantation. Munich Lung Transplant Group.  Intensive Care Med 1998; 24:1173–1180. [PubMed]
  19. Meade MO, Granton JT, Matte-Martyn A, McRae K, aet al. Toronto Lung Transplant Program A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003; 167:1483–1489.[PubMed]
  20. Fujita Y, Nishida O, Sobue K, Ito H, et al.  Nitric oxide inhalation is useful in the management of right ventricular failure caused by myocardial infarction.  Crit Care Med 2002; 30:1379–1381. [PubMed]
  21. Inglessis I, Shin JT, Lepore JJ, Palacios IF, et al. Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. J Am Coll Cardiol 2004; 44:793–798. [PubMed]
  22. Szold O, Khoury W, Biderman P, Klausner JM,  et al. Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature.  Lung 2006; 184:1–5. [PubMed]
  23. SiddiquiAK, Ahmed S. Pulmonary manifestations of sickle cell disease. Postgrad Med J 2003; 79:384–390. [PMC free article] [PubMed]
  24. Reiter CD, GladwinMT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 2003; 10:99–107. [PubMed]
  25. GladwinMT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254–2265. [PubMed]
  26. GladwinMT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol  2001; 38:333–342. [PubMed]
  27. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997; 87:988–990. [PubMed]
  28. Sullivan KJ, Goodwin SR, Evangelist J, Moore RD, Mehta P. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent.  Crit Care Med 1999; 27:2563–2568. [PubMed]
  29. Al Hajeri A, Serjeant GR, Fedorowicz Z. Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2008;(1):CD006957. [PubMed]
  30. Bigatello LM, Stelfox HT, Hess D. Inhaled nitric oxide therapy in adults – opinions and evidence. Intensive Care Med. 2005;31:1014–1016. [PubMed]
  31. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26:15–23. [PubMed]
  32. Michael JR, Barton RG, Saffle JR, Mone M, et al.  Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1372–1380. [PubMed]
  33. Troncy E, Collet JP, Shapiro S, Guimond JG, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157 (5 Pt 1):1483–1488. [PubMed]
  34. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999; 25:911–919. [PubMed]
  35. Park KJ, Lee YJ, Oh YJ, Lee KS, Sheen SS, Hwang SC. Combined effects of inhaled nitric oxide and a recruitment maneuver in patients with acute respiratory distress syndrome. Yonsei Med J 2003; 44:219–226.[PubMed]
  36. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, et al.  Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial.  JAMA  2004; 291:1603–1609.[PubMed]

Related articles

 

Read Full Post »

Expected New Trends in Cardiology and Cardiovascular Medical Devices

Reported: Aviva Lev-Ari, PhD, RN

 

UPDATED on 11/22/2018 – Published Activity on http://pharmaceuticalintelligence.com

  • World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(a) Real Time Highlights and Tweets: Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(b) e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(c)  Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

 

UPDATED on 11/22/2018 – External Sources

  • Latest Medical Devices, Equipment, & Drug Information in Cardiology

Search the latest Cardiology developments in medical devices, equipment and approved drugs. Find new FDA approved procedures, drugs and devices in the MDLinx Product Center.

https://www.mdlinx.com/cardiology/product-center/

  • 5 New Implantable Cardiovascular Technologies to Watch

Recent device technology advances may offer new therapies for atrial fibrillation and heart failure

https://www.dicardiology.com/article/5-new-implantable-cardiovascular-technologies-watch

  • Advances and Trends in Vascular Closure Devices

Faster hemostasis saves nursing time, speeds patient ambulation

https://www.dicardiology.com/article/advances-and-trends-vascular-closure-devices

  • Drivers and Trends in Cardiovascular Device Development: Insights from Key Opinion Leaders

Medical Device Clinical TrialsMedical Device DesignMedical Device Manufacturing & Supply ChainMedical Device Safety and Regulation

https://xtalks.com/webinars/cardiovascular-device-development-insights-from-key-opinion-leaders/

Cardiology Industry 2018

View Trends, Analysis and Statistics.

Reportlinker.com offers immediate download access to top market reports on the Cardiology Industry.

View >

US Cardiology Industry 2018-2022

  • 157 Reports

  • Demographic, Demand, Company Financials…
  • 844 Statistics

  • Demographic, Environment, Market Size…
View >

Global Cardiology Industry 2018-2022

  • 11 Reports

  • Demographic, Supply, Demand…
  • 168 Statistics

  • Market Size, Demand, Company…
View >

European Cardiology Industry 2018-2022

  • 6 Reports

  • Market Description, Statistics, Demographic…
  • 76 Statistics

  • Market Size, Demand, Demographic…
View >

Chinese Cardiology Industry 2018-2022

  • 6 Reports

  • Demographic, Demand, Social Conditions…
  • 29 Statistics

  • Market Size, Demographic, Demand…
View >

UK Cardiology Industry 2018-2022

  • 25 Reports

  • Demographic, Demand, Social Conditions…
  • 394 Statistics

  • Demographic, Environment, Social Conditions…
View >

Australian Cardiology Industry 2018-2022

  • 10 Reports

  • Demographic, Demand, Supply…
  • 123 Statistics

  • Demographic, Environment, Social Conditions…
View >

Canadian Cardiology Industry 2018-2022

  • 6 Reports

  • Demographic, Demand, Forecast…
  • 36 Statistics

  • Demographic, Environment, Social Conditions…
View >

Asian Cardiology Industry 2018-2022

  • 4 Reports

  • Demand, Market Size, Forecast…
  • 19 Statistics

  • Demographic, Environment, Demand…

SOURCE

https://www.reportlinker.com/market-report/Health-Services/115531/Cardiology?utm_source=bingads_usa&utm_medium=cpc&utm_campaign=Healthcare&utm_adgroup=Cardiology_Trends&msclkid=8801b5a8be3910db0eaaee5e55981f3e&utm_term=%2Bcardiology%20%2Btrends&utm_content=Cardiology%20Trends

 

2012

Dr. Joseph Loscalzo of BWH, the moderator of  the  Cardiology Panel — NEJM Dialogue in Medicine, June 22, 2012 has asked the Panel members: What are the new innovations to be foreseen by each member of the Panel which included Panelists:

Emelia Benjamin, BMC

Eugene Braunwald, BWH,

Desmond Jordan, Columbia University Medical Center

Thomas Luscher, Professor and Chairman of Cardiology at the University Hospital Zurich and Director of CardioVascular Research at the Institute of Physiology of the University Zurich, Switzerland.

Craig Smith, Columbia University Medical Center

Dr. Craig Smith of Columbia University Medical Center bet the future of cardiovascular medical devices on the Implantable Synchronized Cardiac Assist Device which has three version, Left ventricle, Right Ventricle or both

Dr. Eugene Braunwald, Founding Chairman, TIMI Study Group (TIMI stands for ‘Thrombolysis In Myocardial Infarction’ and is the name of an Academic Research Organization (ARO) that, since it was founded by Dr. Eugene Braunwald in 1984, has conducted numerous practice-changing clinical trials in patients with cardiovascular disease or risk factors for cardiovascular disease, he has expressed anticipation of the next big and much needed to be available — the Multiple Pill, one drug that is a combination drugs of ASA, TZD, BB, ACE, Statin.

On this Scientific Web Site — Frontiers in Cardiology is one of the Research Categories on Cardiovascular disease, research directed by Dr. Aviva Lev-Ari, noted to be of great relevance to the innovations foreseen by Dr. Craig Smith and by Dr. Brounwald, as expressed by them on June 22, 2012 in Boston, MA

To read on Implantable Artificial Heart — go to 

Lev-Ari, A. (2012G).  Heart Remodeling by Design: Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony

http://pharmaceuticalintelligence.com/2012/07/23/heart-remodeling-by-design-implantable-synchronized-cardiac-assist-device-abiomeds-symphony/

To read on the only currently available Multiple Pill — go to 

Lev-Ari, A. (2012b). Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes

http://pharmaceuticalintelligence.com/2012/05/29/445/

To watch the video of the Cardiology Panel — go to 

http://nejm200.nejm.org/news-and-events/dialogues-in-medicine/?panel=4

To review our post on the Cardiology Panel — go to 

http://pharmaceuticalintelligence.com/2012/08/16/cardiology-panel-nejm-dialogue-in-medicine-june-22-2012/

To review TIMI research results — go to 

http://www.timi.org/ 

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

Relypsa Announces $80 Million Private Financing Transaction

Funds will Support the Advancement of Patiromer (RLY5016) through Phase 3 and NDA Submission

SANTA CLARA, Calif., Aug 15, 2012 (BUSINESS WIRE) — Relypsa, Inc. today announced an $80 million Series C preferred stock financing, including participation from both new and existing investors. Proceeds will be used to fund late-stage development, submission of a new drug application (NDA) and commercial planning for patiromer (RLY5016), the company’s high capacity non-absorbed oral potassium binder being developed for the treatment of hyperkalemia. Relypsa plans to initiate Phase 3 pivotal clinical trials of patiromer this year.

“The strong participation in this financing transaction by our existing investors, as well as the addition of new investors, provides important validation of patiromer’s commercial potential,” stated Gerrit Klaerner, Ph.D., President of Relypsa.

The Series C financing round included existing investors OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures and Mediphase Venture Partners. New investor Sibling Capital, LLC also participated in the transaction.

“Based on the data generated to date in nearly 500 patients, we’re optimistic that patiromer can become an important part of improving the standard of care for patients with chronic kidney disease, especially those suffering from diabetic nephropathy,” said Jonathan T. Silverstein, J.D., General Partner of OrbiMed.

Patiromer is currently being evaluated for the treatment of hyperkalemia in an ongoing Phase 2b study designated AMETHYST-DN. Enrollment of 306 subjects at approximately 50 sites was completed in May 2012. In the study, the efficacy of patiromer is being evaluated in an initial 8-week treatment period, followed by the long-term evaluation of safety and tolerability in a subsequent 44-week extended treatment period.

“As a founding investor in Relypsa, we have been delighted to follow the progress of patiromer from an early stage preclinical candidate to a compelling late-stage product opportunity,” commented Scott M. Rocklage, Ph.D., Managing Partner of 5AM Ventures and Chairman of Relypsa.

About Patiromer and Hyperkalemia

Hyperkalemia is a condition frequently prevalent in patients that suffer from renal impairment, hypertension, diabetes and heart failure. It is characterized by elevated serum potassium levels, which can lead to cardiac arrhythmia and sudden death. Patients with chronic kidney disease are at particular risk for developing hyperkalemia, especially those treated with renin-angiotensin-aldosterone-system (RAAS) inhibitors. Although RAAS inhibition has been shown to protect kidney and cardiac function, as well as prolong life, many patients who could benefit from RAAS inhibitors are untreated or undertreated due to the undesirable side effect of increasing serum potassium.

Patiromer (RLY5016) is a high capacity non-absorbed oral potassium binder being developed for the management of elevated serum potassium levels. Relypsa has completed several clinical trials of patiromer that have demonstrated the preliminary efficacy, safety and tolerability of patiromer for the prevention of hyperkalemia.

About Relypsa, Inc.

Relypsa, Inc. is a clinical-stage pharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa’s lead product candidate is patiromer, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. More information is available at http://www.relypsa.com .

SOURCE: Relypsa, Inc.

Relypsa, Inc.

Jim Johnson,

408-200-9500

Senior VP & CFO
pr@relypsa.com

http://www.fiercebiotech.com/press-releases/relypsa-announces-80-million-private-financing-transaction-0

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

Regulus Therapeutics and UC San Diego to Collaborate on Angiogenic Disease Research Utilizing microRNA Technology

http://www.fiercebiotech.com/press-releases/regulus-therapeutics-and-uc-san-diego-collaborate-angiogenic-disease-resear-0

– UC Discovery Grant award to support collaborative research –

La Jolla, Calif., April 14, 2011 – Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced it is collaborating with researchers at the University of California, San Diego (UCSD) School of Medicine seeking novel treatments for angiogenic diseases using microRNA therapeutics. The research will combine Regulus’ leading microRNA platform with UCSD’s expertise in animal models of angiogenesis to discover anti-angiogenic microRNA-targeted therapies that could be rapidly translated for treatment of human disease.  The collaborative research program was the recent recipient of a UC Discovery Grant that promotes collaborations between the university’s researchers and industry partners.  Financial terms of the grant were not disclosed.

“We are pleased to collaborate with leading scientific institutes like UCSD and to provide industry support for programs such as the UC Discovery Grant,” said Hubert C. Chen, M.D., Regulus’ vice president of translational medicine. “Regulus continues to demonstrate a leadership position in the field of microRNA therapeutics and is committed to forging partnerships with leading academic and clinical laboratories to advance microRNA biology and therapeutic discovery.  Our network of nearly 30 academic collaborations assists us with the investigation of new microRNAs and supports microRNA discovery efforts that feed the Company’s pipeline.”

Angiogenesis, which is the formation of new blood vessels, is an important event that contributes to the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis.  microRNAs have been implicated in regulating biological networks involved in angiogenesis.

“Our research published last year in Nature Medicine demonstrated that microRNA-132 functions as a novel angiogenic switch that turns on angiogenesis in quiescent endothelial cells, and that targeting with an anti-miR-132 decreases blood vessel formation,” said David A. Cheresh, Ph.D., professor of pathology in the UCSD School of Medicine, associate director for translational research at UCSD Moores Cancer Center and principal investigator on the grant. “The objective of our collaborative work with Regulus is to advance these initial discoveries and discover additional microRNAs involved in angiogenic diseases.”

The UC Discovery Grant program promotes collaborations between the university’s researchers and industry partners in the interest of supporting cutting-edge research, strengthening the state’s economy and serving the public good.

About microRNAs

The discovery of microRNA in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 700 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome. microRNAs have been shown to play an integral role in numerous biological processes, including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression or function, has been shown to be significantly altered in many disease states, including cancer, heart failure and viral infections. Targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of microRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function opens potential for a novel class of therapeutics and offers a unique approach to treating disease by modulating entire biological pathways. To learn more about microRNAs, please visit http://www.regulusrx.com/microrna/microrna-explained.php.

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years and tested in more than 5,000 humans. In addition, Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus is advancing microRNA therapeutics towards the clinic in several key areas including hepatitis C infection, immuno-inflammatory diseases, fibrosis, oncology and cardiovascular/metabolic diseases. Regulus’ intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics. This alliance is focused initially on fibrosis. For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus’ business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Any statement describing Regulus’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulus’ management, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus’ programs are described in additional detail in each of Alnylam’s and Isis’ annual report on Form 10-K for the year ended December 31, 2010, which are on file with the SEC. Copies of these and other documents are available from either Alnylam or Isis.

Read Full Post »

Regression: A richly textured method for comparison and classification of predictor variables: The multivariable Case

Author: Larry H. Bernstein, MD

 e-mail: plbern@yahoo.com.

Keywords:  bias correction, chi square, linear regression, logistic regression, loglinear analysis, multivariable regression, normal distribution, odds ratio, ordinal regression, regression methods

Abstract

Multivariate statistical analysis is used to extend this analysis to two or more predictors.   In this case a multiple linear regression or a linear discriminant function would be used to predict a dependent variable from two or more independent variables.   If there is linear association dependency of the variables is assumed and the test of hypotheses requires that the variances of the predictors are normally distributed.  A method using a log-linear model circumvents the problem of the distributional dependency in a method called ordinal regression.    There is also a relationship of analysis of variance, a method of examining differences between the means of  two or more groups.  Then there is linear discriminant analysis, a method by which we examine the linear separation between groups rather than the linear association between groups.  Finally, the neural network is a nonlinear, nonparametric model for classifying data with several variables into distinct classes. In this case we might imagine a curved line drawn around the groups to divide the classes. The focus of this discussion will be  the use of linear regression  and explore other methods for classification purposes.

Introduction

Multivariate statistical analysis extends regression analysis and introduces combinatorial analysis for two or more predictors.   Multiple linear regression or a linear discriminant function would be used to predict a dependent variable from two or more independent variables.   If there is linear association dependency of the variables is assumed and the test of hypotheses requires that the variances of the predictors are normally distributed.  Linear discriminant analysis examines the linear separation between groups rather than the linear association between groups, and it also requires adherence to distributional assumption. There is also a relationship of analysis of variance as a special case of linear regression, a method of examining differences between the means of two or more groups. A method using a log-linear model circumvents the problem of the distributional dependency in a method called ordinal regression.  Finally, the neural network is a nonlinear, nonparametric model for classifying data with several variables into distinct classes. In this case we might imagine a curved line drawn around the groups to divide the classes.

Regression analysis.

The use of linear regression, linear discriminant analysis and analysis of variance has to meet the following assumptions:

The variables compared are assumed to be independent measurements.

The correlation coefficient is a useful measure of the strength of the relationship between two variables only when the variables are linearly related.

The correlation coefficient is bounded in absolute value by 1.

All points on a straight line imply correlation of 1.

Correlation of 1 implies all points are on a straight line.

A high correlation coefficient between two variables does not imply a direct effect of one variable on another (both may be influenced by a hidden explanatory variable).

The correlation coefficient is invariant to linear transformations of either variable.

The correlation coefficient is also expressed as the covariance or product of the deviations of X and Y from their means standardized by dividing by the respective standard deviations.

These assumptions may be valid if the amount of data compared is very large, and if the data is parametric.  This is not necessarily the case.  There are also special applications in laboratory evaluations and crossover studies between methods and instruments that require correction for bias or for differences in the error variance term.

How do we measure the difference if there is any?  We use the t-test (19, 21).   If t is small than the null hypothesis is satisfied and no difference is detected in the means.   The conclusion is that the null hypothesis is accepted and the means are essentially the same .  However, the ability to accept or reject the null hypothesis is dependent on sample size, or power.  If the null hypothesis is rejected, bias has to be suspected.  This is useful when analyzing certain data, where the results of OLS are unsatisfactory. This test is here applied to linear increasing values of Y on X measured by A and B methods.   Of course the measurements are plotted and a line is fitted to the scatterplot.   OLS gives the fit of the line based on the least squares error, where the slope of the line is given by (20,22).

B = å (xi – mean x)yi .

å(xi – mean x)2

It is assumed that there are n pairs of values of x and y, and xi and yi denote the ith pair of values.   The slope defines the regression line of y on x.  An intercept that differs from zero is the bias.  It is worthwhile to mention that there is a difference here between the correlation measurement and the least squares fit of y on x.   We are measuring X by methods A and B.  We can then determine that the is a linear association with r valued between 0 and 1 (-values excluded).  In the case of the regression model, we are predicting B from A by plotting B on y from A on x.   Of course, experimentally, we are expecting the prediction to hold over a range of measurements, and the agreement drops off at some value of the coordinates (xi, yi).

Multiple regression is an extension of linear regression where the dependent variable is predicted by several independent variables.

In this case, the extended equation is (23)

Y = b0 + b1x1 + b2x2 + b3x3 …bnxn.

The model assumes a linear relationship between many predictor variables and the dependent variable.  The model usually assumes that the independent variables are not correlated with each other, which may not be the case.  The model can be tested by stepwise removal of predictor variables to assess their contribution to the model.     The model is  considered to be parametric, and so it requires that the inputs are normally distributed.  The bs (or betas) are also partial correlation coefficients.  The partial F test is the measure of the contribution of each variable after all the variables are in the equation.

Figures 1-3 are scatterplots of eGFR (glomerular filtration rate calculated by MDRD equation) and of hemoglobin vs Nt-proBNP, and a boxplot of Nt-proBNP by WHO criteria for anemia. Figure 2 is a 3D plot of NT-proBNP spliced by eGFR and hemoglobin.  The linear regression model is presented in Table I.  The correlation coefficient (R ) for the model is weak, but not insignificant. What do you think is the effect of the large variance in the dependent variable?   Figure 3 is a 3D plot of the eGFR and hemoglobin vs a transformed variable – age normalized 1000*Log(Nt-proBNP)/eGFR.  The variance is reduced on the transformed variable.  Table II is the regression model on the data.  The correlation coefficient R is improved.

Analysis of variance (ANOVA) and Analysis of covariance (ANCOVA)

ANOVA is used if the dependent variable is continuous and all of the independent variables are categorical.   One-way ANOVA is used for a single independent variable, and multi-way ANOVA is used for multiple independent variables.   The ANOVA is based on the general linear model.   The F-test is used to compare the difference between the means of groups.   The independent variable has discrete values is not used as a measure.   The t-test can be used between each pair in the groups.   The goal of ANOVA is to explain the total variation found in the study.   An example of this application is shown in Figure 4.

Figure 4.  BNP determined within ejection fraction above or within 40

Figure 5 is the means and 95% confidence intervals for a comparison of D-dimer and positive or negatine venous duplex scans.  There are only two variables so the corresponding ANOVA is one-way.  The F-value is high and corresponds to a high t in the t-test.  F is the same as t2 and p = 0.0001 (Table III).  Our interest here is in multiple variables so we’ll hold the discussion of difference testing between two variables.

Figure 5.

Table III.

If some of the independent variables are categorical (nominal, ordinal or dichotomous) and some are continuous ANCOVA is used.   The ANCOVA procedure first adjusts the dependent variable on the basis of the continuous independent variable and then does ANOVA on the adjusted dependent variable.

Generalized linear and generalized additive models

Generalized linear models transform the response by assuming that a transformation of the expected response is a linear function of the predictor variables.   The variance of the response is a function of the mean response.   When the relationship between the parameters is not linear, a generalized linear model can’t be used.   A generalized additive model can be used to fit nonlinear data-dependent functions of the predictor.   Tree-based models are used for exploratory analysis and are related to clustering, which is a method for studying the structure of the data, creating clusters of data with similar characteristics.

Discriminant analysis

The discriminant analysis is a modification of the general linear regression model.   The method is used to assign data to any of distinct classes as the dependent variable.   The linear regression model predicts based on a linear relationship between the dependent and the independent variables.   They are codependent.   In the discriminant function they are independent.   The function determines a separation between the classes to which the data assigns patients.   The goal is to assign a new incoming patient based on the independent variables to one of the different groups.   The mathematical function can be linear, quadratic, or another function.   The stepwise linear regression with removal or addition of variables is viewed in the same way.   However, the discriminant function produces a separation between the classes rather than through them.  The same qualifications for the method fit pertaining to distributional assumptions that applies to multiple linear regression applies to the linear discriminant function, but the analysis of data on congestive heart failure, renal insufficiency and anemia partitioned with NT-proBNP, creatinine, age and hemoglobin concentration shown in Figure 6 and Table IV uses a quadratic equation.  I re-classify the data using the transformed variable age-normalized 1000*Log(NT proBNP)/eGFR presented in Figure 7 and Table V.  The use of the logarithmic transform and removal of age and hemoglobin as predictors give impressive results.

Figure  6.

Table IV.

Figure 7.

Table V.

Mahalanobis D2

The euclidean distance between two coordinates having the position (x1y1), (x2y2) is given by the distance D = ([x1 – x2]2 + [y1 – y2]2)1/2.   This is generalized for N-dimensional space, and the square of the distance is D2.   The two points are the centroids in a cloud of points in space separated by D, the euclidean distance between the points in an N-dimensional space.   The multiplication of a vector and a variance-covariance matrix T-1 yields the linear discriminant functions.   The Mahalanobis distance can be used to evaluate the distances of centroids and also the distances of objects towards the centroid of their class.

Logistic regression

The linear probability model (logistic regression) is the standard regression model applied to data for which the dependent variable is dichotomous (0,1). It fits a logistic function to the dependent variables valued at 0 or 1 and estimates the probabilities associated with each observation (24).  The predicted values from the model are interpreted as a probability that the response is a 1.  The test of significance of the model is the Maximum Likelihood Estimator (MLE).  The significance is determined by adjusting the parameters to maximize the likelihood of the observed data arising from the linear sum of the variables.

There are problems in using the linear probability model (49).

The residuals don’t have a constant variance so that estimates from regression are not best linear unbiased, therefore, not minimum variance.

Standard errors of regression coefficients can be erroneous giving invalid confidence intervals.

The predicted values from regression can range outside the interval [0,1], whereas probabilities are bounded by that interval

The linearity assumption inherently imposes constraints on the marginal effects of predictor variables that are not taken into account by the OLS estimation.

The linearity assumption implies that the marginal effect of a predictor is constant across its range.

The usual r squared measure is problematic.

Ordinal regression

I now turn to the application of a special nonparametric regression program developed by Jay Magidson (GOLDmineR; Statistical Innovations Inc., Belmont, MA), referred to as Ordinal regression, or universal regression (25-28).   Let’s look at the application of this tool, which makes outcomes analysis easy.   This method brings a powerful tool to the analysis of laboratory data for clinical validation of diagnostic tests.  It overcomes serious limitations of logistic analysis when there is more than two possible outcomes to consider.   This has become more important as we introduce tests that have results that are affected by morbid conditions so that a range of probabilities might be associated with scaled “dummy values” of the test (possibly because of hidden or unspecified variables).

Ordinal dependent variables are multivalued and have an ordered relationship to the predictor variable(s).   Magidson (25-28), inspired by the work of Leo Goodman (29,30), suggests the existence of a single regression model that can accomodate dependent variables of any metric – dichotomous, ordinal, or continuous.   This supermodel holds true under the assumption of bivariate normality and under other distributional assumptions and subsumes linear distribution and logistic regression as special cases (25).    It uses a log odds model fit and the odds ratio is obtained from the log(odds ratio).   In the linear probability model, the coefficients (bi) are partial correlation coefficients.   In the logit model the coefficients are partial log(odds-ratio).

The monotonic regression of X on Y is described by:

J

E(Y|X = x) = å   Pj.x yj

J=1

Where Pj.x, the conditional probability of the occurrence of Y=yj (an ordinal dependent variable) given X=x (qualitative or quantitative predictor variables), is estimated from a sample of N observations using 2 steps.

1)      Conditional logits Yj.x are predicted using the generalized logit model, where Yj.x*  is: Yj.x = aj + (b1x1* +  b2x2*  + bMxM*)yj*    j= 1,2,…, J.
The Y-scores, which determine the ordering and relative spacing of the J outcomes, may be specified or if unspecified, they are treated as model parameters and estimated with other parameters.   Yj* , the relative Y-score, is the difference between yj and some Y-reference score y0 defined as a weighted average of the original Y-scores.

2)      The predicted logits are transformed to predicted probabilities using the identity:

J

Pj.x º exp(Yj.x)/å exp(Yj.x)

J=1

For a given X=x, the generalized logit is defined as

Yj.x º ln(Pj.x/P0.x)

where Pj.x is the conditional probability of the jth outcome occurring when X=x

J

and P0.x =  P (Pj.x)ej

j=1

I performed a nonparametric regression using the universal regression program GOLDminer, developed by Jay Magidson (25-28) at Statistical Innovations, Belmont, MA.  The universal regression program is a logistic regression if the dependent variable is a binary outcome, and it is a polytomous regression if there are more than two dependent variables, but it can accommodate a paired comparison of covariates.  The measure of association is phi and R2.  The measure of fit is L2 (chi square).  The logarithmic form transforms into a probability model, which we aren’t concerned with here.

Graphical Ordinal Logit Display (GOLDminer)

I have mentioned the nonparametric universal regression of Magidson (25-28), based on work with log-linear modeling with Prof. Leo Goodman (29,30).  The logistic regression and linear regression models can be viewed as special cases of this more general model.  This regression model has greatest use for examining structure in data where there are more than two dependent variables, and the independent variables are scaled to intervals (25-28).  The model is more general than the logistic regression and is not constrained by the conditions encountered with logistic regression identified above.

I cite a number of publications of its use in clinical laboratory outcomes analysis.

Example  1.  The association between predictors of nutrition risk and malnutrition risk

I use here data obtained by Linda Brugler and coworkers at St.FrancisHospital in Wilmington, DE (31) that examines association between the malnutrition assessed before intervention with three predictors of malnutrition risk.  Poor oral intake and malnutrition related diagnosis are categorical, and the laboratory-derived serum albumin is scaled to form an ordinal predictor.   The strength of the predictors is given by Table VI:

Table VI.  Ordinal regression model for combined 3 predictors of malnutrition risk.

The model is defined by the following:  L2 = 267.68, R2 = 0.405, phi = 1.1134,

Df (3, 42), p = 9.7e-58.

Example 2:  Ordinal regression for thalassemia risk

Table VII shows the odds-ratios for the combinatorial scaled results of Mentzer score (ratio of MCV: red cell count), MCV, and Hgb A2(e)(by electrophoresis is higher than by HPLC).  The presence of only a single positive test gives an unlikely result for thalassemia, while two or more positive tests give a high likelihood of thalassemia.   This is summarized as follows: 0,0,0-0,0,1-0,1,0-1,0,0 = 0; 1,1,1-1,0,1-0,1,1-1,1,0 = 1.

Table VIII.   Expected Odds Ratios – Diagnosis Thalassemia

Example 3. Ordinal regression for risk of newborn respiratory distress syndrome

A study by Kaplan, Chapman and coworkers (32) extending work by Bernstein and Rundell (33) looked at the relationship between gestational age and RDS of the newborn and used the ordinal regression model to predict expected outcomes (33).  Table IX gives probabilities for the prediction of risk.

Table IX.   Probabilities of RDS given by gestational age and S/A ratio.

Example 4.  Prediction of myocardial infarction risk by EKG and troponin T at 0.1 ng/ml

Bernstein, Zarich and Qamar (34) carried out a study in which the physicians were blinded to the troponin T results.  A randomized prospective study of over 800 patients followed (35-37).  The chest pain characteristics, EKG findings and troponin T results were reviewed for consecutive patients entered into the study (34).   EKG results were scaled as: negative, nonspecific, 0; ST depression or T wave inversion, 1, ST elevation or new Q-wave, 2.  Troponin T was scaled as follows: 0-0.075 ng/ml, 0; 0.076-0.099, 1; > 0.1.The diagnoses were as follows: noncardiac, cardiac and nonischemic, 1; Unstable angina with MI ruled out, 2; non ST or ST elevation MI, 3.  Table X is the table of odds ratios and probabilities.

Table X. Ordinal regression of EKG and troponin T on diagnoses

Ovarian Cancer Survival

Rosman and Schwartz have reported a relationship between CA125 post-chemotherapy of ovarian carcinomatosis and serum half-life of CA125.  We examined a published data set provided by Dr. Martin Rosman.  Data were analyzed from 55 women who were treated at YaleUniversity, had an evaluable CA125 half-life (t1/2), and were followed for disease recurrence for at least 3 years.  We modeled survival or remission for ovarian cancer using operative findings, stage, and CA125 halflife (46).  Figure 9 is a plot of the CA125 elimination half-life vs the Kullback-Liebler distance using the data provided by Dr. Martin Rosman. The K-L distance is the difference between the total entropy of the data in which association is removed and the observed entropy for each value of CA125.  The t1/2 is 10 days.  What Rudolph and Bernstein (43) have referred to as effective information is KL distance. This was done to determine the value of CA125 that best predicts survival.

Figure 9 CA125 halflife

The next step was to carry out a Kaplan Meier survival plot with Cox regression on the data vs the time to death or remission.  A survival of 30 months is considered a cure.  A survival less is considered a remission.  Some patients died only shortly into chemotherapy.   The study result is shown in Figure 11.

Figure 10.  Kaplan Meier plot

We also examined the associations between OPERATIVE FINDINGS and CA125 to REMISSION and NONREMISSION or RELAPSE using a universal regression model under bivariate normality with estimation of generalized odds-ratios developed by Jay Magidson (Statistical Innovations, Inc., Belmont, MA).  It uses a parallel log-odds model based on adjacent odds to describe the data.  The universal regression is carried out after scaling the continuous variables with intervals we determined as follows: halflife- 0-5, 6-10, 11-15, 16-20, >20.   A crosstabulation is constructed using the scaled variables as treatment vs. the effect (full, short remission or none), to obtain the frequency tabulation of treatment level vs remission, relapse or nonremission.

Table XI is a cross-tabulation of the observed and expected outcome frequencies in remission (rem), short remission (short,< 30 months) and non-remission (none) versus the scaled half-lives.   Relapse and failure to achieve remission were combined into one outcome class.  The means and standard error of the means (SEM) of half-life versus remission or non-remission/relapse are effectively separated (F=7.42, p < 0.01) as follows: Remission, 7.9, 2.8, [19];  Relapse/Non-remission, 17.4, 2.05, [36].

Table XII.  Observed and expected odds and odds-ratios of remission, relapse and no response by half-life

Perspective for the Future

Linear regression has been used extensively for methods comparison and for quality control, exclusively based on distributional assumptions and distance from the center of the population sample.   This is essential to analytical chemistry principles, but it has reached a limit.  The last 30 years has seen the development of very powerful regression tools that are not dependent on distributional assumptions and that move the method into classification and prediction.  The development of the Akaike Information Criterion (38-40) brought together two major disciplines that had separate developments, information theory and statistics.   The work by Bernstein et al. (41-42) in predicting myocardial infarction using bivariate density estimation, and with Kullback-Liebler Distance (43, 44), an extension of work by Rypka (45) is closely related. The use of tables and the scaling of data has been the dominant approach to statistics that uses ordinal and categorical data in outcomes research.  This has become a powerful method used in studies of placebo and drug effects.   The approach is readily amenable to studies of laboratory tests and outcomes.   Outcomes studies will be designed and carried out for laboratory tests that will ask questions appropriate for the clinical laboratory sciences, and that will not be subordinated to pharmaceutical evaluations, which currently have exclusion criteria that are inappropriate for laboratory investigations.

Summary

Regression has a long history in the development of modern science since the 18th century.  Regression has had a role in the emergence of physics, anthropology, psychology, and chemistry.  But its development was initially tied to linear association and assumption of normal distribution.   There are many associations that are tied to frequency of discrete events.  The use of chi-square as a measure of goodness of fit has such a tie to genetic analysis and to classification tables.   The importance of outcomes management and the recognition of a multivariable data structure that needs to be explored leads us to a new domain of regression models and includes an assumption that the dependent variable may not be know with certainty.  This is the case with the emerging models known as mixture models, structural equation models and latent class models.  This type of model is not traditionally a regression model and looks at defined variables and also unmeasured, hidden or latent variables (factors) in the model.  However, there are factor analysis and regression forms of the LCM that are included in the LCM software releases of Statistical Innovations, Inc. (Latent Gold). This important subject is beyond the scope of this review, but Demidenko (47) has written an excellent text on the subject.

References:

19. Hoel PG. Elementary Statistics, Testing Hypotheses: The difference between two means. Chapter 3.3. pp133-117. 1960. Wiley, New York.

20. Hoel PG. Ibid. Regression. Chapter 9. pp141-153.

21. Norman GR, Streiner DL. Biostatistics: The Bare Essentials. Two repeated observations: The paired t-test and alternatives. Chapter 10. pp89-93. 2000, BC Deckker, Hamilton, Ont., Canada.

22. Norman GR, Streiner DL. Ibid. Simple regression and correlation. Chapter 13. pp118-126.

23. Norman GR, Streiner DL. Ibid. Multiple regression. Chapter 14. pp127-137.

24. Norman GR, Streiner DL.Ibid. Logistic regression. Chapter 15. pp139-144.

25.  Magidson J.  “Multivariate Statistical Models for Categorical Data,” Chapters 3 & 4   in Bagozzi R, Advanced Methods of Marketing Research, Blackwell, 1994.

26.  Magidson J. Introducing a new graphical method for the analysis of an ordered categorical response – Part I. Journal of Targeting, Measurement and Analysis for Marketing (UK). 1995; IV(2):133-148.

27.  Magidson J.  Introducing a new graphical model for the analysis of  an ordered categorical response – Part II. Ibid. 1996;IV(3):214-227.

28.  Magidson J.  Maximum likelihood assessment of clinical trials based on an ordered categorical response. Drug information Journal. 1996;30:143-170.

29.   Goodman LA.  Simple models for the analysis of associations in cross-  classifications having ordered categories.  Journal of the American Statistical Association. 1979;74: 537-552.  Reprinted in The Analysis of Cross-Classified Data Having Ordered Categories. 1984, HarvardUniversity Press.

30. Goodman LA.  Association models and the bivariate normal for contingency tables with ordered categories. Biometrika 1981;68:347-355.

31.Brugler L, Stankovic AK, Schlefer M, Bernstein L. A simplified nutrition screen for hospitalized patients using readily available laboratory and patient information. Nutrition 2005;21:650-658.

32. Kaplan LA, Chapman JF, Bock JL, Santa Maria E, Clejan S, et al. Prediction of respiratory distress syndrome using the Abbott FLM-II amniotic fluid assay. Clin Chim Acta 2002;326[1-2]:61-68.

33.  Bernstein LH, Stiller R, Menzies C, McKenzie M, Rundell C. Amniotic fluid    polarization of fluorescence and lecithin/sphingomyelin ratio decision criteria assessed. Yale J Biol Med 1995; 68(2):101-117.

34.  Bernstein LH, Qamar A, McPherson C, Zarich S.   Evaluating a new graphical   ordinal logit method (GOLDminer) in the diagnosis of myocardial infarction utilizing clinical features and laboratory data.   Yale J Biol Med 1999; 72:259-268.

35. Bernstein L, Bradley K, Zarich S. GOLDmineR: Improving Models for Classifying Patients with Chest Pain. Yale J Biol Med 2002;75: 183-198.

36. Zarich S, Bradley K, Seymour J, Ghali W, Traboulsi A, et al. Impact of troponin T determinations on hospital resources and costs in the evaluation of patients with suspected myocardial ischemia. Amer J Cardiol 2001;88:732-6.

37. Zarich SW, Qamar AU, Werdmann MJ, Lizak LS, McPhersonCA, Bernstein LH. Value of a single troponin T at the time of presentation as compared to serial CK-MB determinations in patients with suspected myocardial ischemia. Clin Chim Acta 2002;326:185-192.

38. Akaike H. Information theory and an extension of maximum likelihood principle.    In B.N. Petrov and F. Csake (eds.), Second International Symposium on Information Theory. 1973, Akademiai Kiado, pp 267-281, Budapest.

39. Akaike H. A new look at the statistical model identification.  IEEE Transactions on Automation Control, AC-19, 1974; 716-723.

40. Dayton CM. Information Criteria for the Paired-Comparisons Problem.  American Statistician. 1998;52: 144-151.

41. Bernstein LH, Good IJ, Holtzman GI, Deaton ML, Babb J:  Diagnosis of myocardial infarction from two enzyme measurements of creatine kinase isoenzyme MB with use of nonparametric probability estimation.  Clin Chem 1989;35:444-7.

42. Bernstein LH, Good IJ, Holtzman GI, Deaton ML, and Babb J. Diagnosis of heart attack from two enzyme measurements by means of bivariate probability density estimation: statistical details. J Statistical Computation and Simulation. 1989.

43. Rudolph RA, Bernstein LH, Babb J. Information-induction for the diagnosis of myocardial infarction. Clin Chem 1988;34:2031-8.

44. Kullback S, Liebler RA. On information and sufficiency. Ann Mathematical Statistics 1951;22:79-86.

45. Rypka EW. Methods to evaluate and develop the decision process in the selection of tests. Clinics in Laboratory Med 1992;12[2]: 351-385.

46. Bernstein LH. Outcomes-based Decision Support: How to Link Laboratory Utilization to Clinical Endpoints. Chapter 8. Pp91-128. In Bissell MG, ed. Laboratory-Related Measures of Patient Outcomes: An Introduction. 2000. AACC Press. Washington, DC.

47. Demidenko E.  Mixture models: Theory and applications.  2004.  Wiley-Interscience. Hoboken, NJ.

48. Martin RF. General Deming regression for estimating systematic bias and confidence interval in method-comparison studies. Clin Chem 2000;46:100-104.

49. Magidson J.  Opportunities grow on trees. A general alternative to linear regression. Monotonic regression of dichotomous, ordinal and grouped continuous dependent variables.  1998. Statistical Innovations, Inc. Belmont, MA.

 Figures and Tables Version 8 Multivariable

Table I.  Regression of eGFR and hemoglobin to predict Nt-proBNP

Step number : 0
R : 0.376
R-square : 0.141

 

In Effect Coefficient Standard Error Std.
Coefficient
Tolerance df F-ratio p-value
1 Constant
2 eGFR -83.499 14.063 -0.297 0.951 1 35.256 0.000
3 Hgb -910.224 260.436 -0.175 0.951 1 12.215 0.001

Information Criteria

AIC 7785.028
AIC (Corrected) 7785.139
Schwarz’s BIC 7800.628

 

Dependent Variable NTproBNP
(pg/ml)
N 365
Multiple R 0.376
Squared Multiple R 0.141
Adjusted Squared Multiple R 0.137
Standard Error of Estimate 10287.156

Analysis of Variance

Source SS df Mean Squares F-ratio p-value
Regression 6.309E+009 2 3.155E+009 29.809 0.000
Residual 3.831E+010 362 1.058E+008

Table II. Linear regression of NKLog(Nt-proBNP0/eGFR by eGFR and hemoglobin

Log transform flattens the high Nt-proBNP scale and eGFR and age are normalized

R

:

0.597
R-square

:

0.357

 

In Effect Coefficient Standard Error Std.
Coefficient
Tolerance df F-ratio p-value
1 Constant
2 eGFR -1.873 0.144 -0.573 0.933 1 170.011 0.000
3 Hgb -4.259 2.436 -0.077 0.933 1 3.056 0.081

Information Criteria

AIC 4299.786
AIC (Corrected) 4299.899
Schwarz’s BIC 4315.331

 

Dependent Variable NKLogNTGFR
N 360
Multiple R 0.597
Squared Multiple R 0.357
Adjusted Squared Multiple R 0.353
Standard Error of Estimate 94.260

Regression Coefficients B = (X’X)-1X’Y

Effect Coefficient Standard Error Std.
Coefficient
Tolerance t p-value
CONSTANT 256.151 27.745 0.000 . 9.232 0.000
MDRD_GFR -1.873 0.144 -0.573 0.933 -13.039 0.000
Hgb -4.259 2.436 -0.077 0.933 -1.748 0.081

Table III. One-way ANOVA of D-dimer for positive and negative scans

Dependent Variable D_DIMER
N 817

Analysis of Variance

Source Type III SS df Mean Squares F-ratio p-value
VENDUP 43456570.851 1 43456570.851 68.278 0.000
Error 5.187E+008 815 636461.763

Table 4.   Discriminant function for CHF, renal insufficiency and anemia by age, NT-proBNP, creatinine and hemoglobin

Group Frequencies
0 1 2
135 335 235
Group Means
  0 1 2
NTproBNP (pg/ml) 1516.369 5964.054 12902.662
Creatinine 0.716 1.654 2.103
Hgb 11.972 11.533 11.305
Age 60.570 71.373 74.966
Between Groups F-matrix
df : 4 699
  0 1 2
0 0.000
1 23.445 0.000
2 45.108 11.788 0.000

Wilks’s Lambda

Lambda

:

0.778

df

:

(4,2,702)

Approx. F-ratio

:

23.337

df

:

(8,1398)

p-value

:

0.000

 

Classification Functions
  0 1 2
CONSTANT -32.018 -35.196 -37.394

Variable

F-to-remove Tolerance
5 NTproBNP
(pg/ml)
13.489 0.801
6 Creatinine 21.368 0.799
7 Hgb 0.190 0.928
3 Age 38.632 0.948
Test Statistic
Statistic Value Approx. F-ratio

df

p-value
Wilks’s Lambda 0.778 23.337 8 1398 0.000
Pillai’s Trace 0.226 22.295 8 1400 0.000
Lawley-Hotelling Trace 0.279 24.382 8 1396 0.000

Table V.  The DFA calculations for Figure 9.

Group Frequencies
  0 1 2
221.000 631.000 571.000
Means
NKLgNTproGFRe 15.589 55.971 81.159
MDRD 123.130 61.940 48.748
Group 0 Discriminant Function Coefficients
  NormKLgNTproGFR-
e
MDRDest Constant
NKLgNTproGFRe -0.015
MDRD -0.001 0.000
Constant 0.588 0.052 -15.590
Group 1 Discriminant Function Coefficients
  NormKLgNTproGFR-
e
MDRDest Constant
NKLgNTproGFRe 0.000
MDRD 0.000 -0.001
Constant 0.024 0.089 -12.106
Group 2 Discriminant Function Coefficients
  NormKLgNTproGFR-
e
MDRDest Constant
NKLgNTproGFRe 0.000
MDRD 0.000 -0.001
Constant 0.015 0.147 -13.077
Between Groups F-matrix
df : 2 1419
  0 1 2
0 0.000
1 236.650 0.000
2 335.228 21.342 0.000

Wilks’s Lambda for the Hypothesis

Lambda

:

0.671

df

:

(2,2,1420)

Approx. F-ratio

:

156.542

df

:

(4,2838)

p-value

:

0.000

 

Classification Matrix (Cases in row categories classified into columns)
  0 1 2 %correct
0 206 15 0 93
1 237 363 31 58
2 69 459 43 8
Total 512 837 74 43
Jackknifed Classification Matrix
  0 1 2 %correct
0 205 16 0 93
1 237 363 31 58
2 69 462 40 7
Total 511 841 71 43
Test Statistic
Statistic Value Approx. F-ratio

df

p-value
Wilks’s Lambda 0.671 156.542 4 2838 0.000
Pillai’s Trace 0.330 140.347 4 2840 0.000
Lawley-Hotelling Trace 0.488 173.026 4 2836 0.000
Canonical Discriminant Functions
  1 2
Constant -1.912 -1.075
NKLgNTproGFRe 0.001 0.009
MDRD 0.028 0.008
Canonical Discriminant Functions : Standardized by Within Variances
  1 2
NKLgNTproGFRe 0.085 1.061
MDRD 1.026 0.284
Canonical Scores of Group Means
  1 2
0 1.576 0.034
1 -0.122 -0.069
2 -0.476 0.063

Table VI  Ordinal regression model for combined 3 predictors of malnutrition risk.

Predictor                                              L2                     p                      exp(beta)

Poor oral intake                                    60.29               8.2e-15              5.3

Malnutrition related condition    46.29               1.0e-11              3.06

Albumin                                                152.01             6.3e-35              3.16

Table VII.   Expected Odds Ratios – Diagnosis Thalassemia

Odds-Ratios

Me,M,A2(e)                 Thalassemia

1,1,1                                 9713

1,1,0                                 1696

1,0,1                                   263

0,1,1                                   212          

1,0,0                                     46

0,1,0                                     37

0,0,1                                       6

0,0,0                                       1

Table VIII.   Probabilities of RDS given by gestational age and S/A ratio.

Dependent variable: Respiratory outcome (Resp_Sca)

Predictors: Surfactant to albumin (S/A) Ratio_45: 0, > 45; 1, 21-44; 2, < 21;

Gestational age at delivery: 0, > 36; 1, 34-36; 2, < 34.

S/A Ratio_45               p = 8.7*10-22

Gestational Age at Delivery Scaled        p = 4.2*10-9

Combined variables: ChiSq = 130.14,   p = 5.1*10-28,   R2 = 0.433,   phi = 0.8231,   exp(beta) = 2.16 (S/A),   1.88 (GA)

Definition (S/A, GA) Exp. Probabilities Exp. Odds-Ratios
0-20, < 34 0.84 4427
0-20, 34-36 0.64 668
21-44, < 34 0.57 441
0-20, > 36 0.31 101
21-44, 34-36 0.25 67
> 45, < 34 0.19 44
21-44, > 36 0.06 10
> 45, 34-36 0.04 7
> 45, > 36 0.01 1

Table IX. Ordinal regression of EKG and troponin T on diagnoses

Association Summary               L²                     df         p-value             R²        phi

Explained by Model                  206.52             2          1.4e-45            0.686   1.3856

Residual                                         48.64               14        1.0e-5

Total                                               255.16             16        4.5e-45

Odds Ratios and probabilities for diagnoses

average                        1                2                              0          1          2

score                            0.00        0.00

2,3       2.87                             466.82   10086.03         0.01     0.11     0.88

2,2       2.67                             105.78    1087.95           0.04     0.20     0.75

1,3       2.64                             95.35          931.05            0.05     0.21     0.74

2,1       1.95                             23.97          117.35            0.26     0.27     0.47

1,2       1.87                             21.61           100.43           0.29     0.26     0.45

0,3       1.79                             19.48             85.95           0.32     0.26     0.42

1,1       0.67                             4.90                10.83          0.73     0.15     0.12

0,2       0.61                             4.41                   9.27          0.75     0.14     0.11

0,1       0.12                             1.00                 1.00            0.95     0.04     0.01

Table X.  Observed and expected odds and odds-ratios of remission, relapse and no response by half-life

Half-life          exp. odds     exp. odds-ratios

(range, days)      Rem    short    none     Rem   short  none

> 20                           1      4.16    17.11      1    12.49  56.07

16-20                         1      2.21     4.84      1     6.64  44.16

11-15                          1      1.18     1.37      1     3.53  12.49

6-10                            1     0.63     0.39      1     1.88   3.53

< 6                               1     0.33     0.11       1       1         1

HL-ref                         1    0.33      0.11       1       1         1

Figure 1.  log_NT-proBNP vs eGRF

Figure 2.   Boxplots of NT-proBNP and WHO criteria

Figure 3.  NT-proBNP vs Hb

Figure 4.   3D plot of NT-proBNP, MDRD eGFR, Hb

Figure 5.   3D plot of Normalized K*Log_NTproBNP/eGFR, eGFR, Hb

Figure  6. D-dimer Confidence Intervals vs Imaging

Figures 7 & 8.   Canonical Scores Plots

Figure 9.  Entropy Plot of CA125 halflife (x) vs Effective Information
(Kullback Entropy) showing sharp drop in Entropy at 10 days (equivalent to information added to resolve uncertainty).  AS developed by Rosser R Rudolph

Figure 10.  Kaplan Meier Plot of CA125 half-life vs Survival in Ovarian Cancer

Read Full Post »

Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents

Author: Aviva Lev-Ari, PhD, RN

Real medical ethical dilemmas involved in physician assignment of patients to participate in Clinical Trials

Randomized controlled clinical trials have become the method of choice or the standard technique for obtaining scientific information to be used in changing diagnostic or therapeutic methods. The use of this technique creates an ethical dilemma (Hellman and Hellman, 1991).

Physicians using a randomized clinical trial are cast in two opposing roles at the same time: clinicians and researchers. As clinicians, they have an ethical commitment to individual patients: to practice professionally in an empathetic profession that is concerned with each patient as an individual. By entering into a relationship with an individual patient, the physician assumes obligations and commitments to act always in the patient’s best interest, derived from values of loyalty and the virtue of fidelity to his/her patients. Modifications of these relationships, otherwise dyadic relationship, occurs when a physician assumes legal obligations to report wounds of a suspicious nature and certain infectious diseases. Such obligations do not conflict with the physician’s ethical obligation to act in the best medical interests of his/her patient. Social concerns have pre-empted physician reporting of disease manifestations which are suspected to have public health bearing (Hellman and Hellman, 1991).

The other role assumed by a physician participating in randomized clinical trials, is that of a scientific researcher, committed to determine the validity of formally constructed hypotheses and their testing. Results of scientifically formulated studies using the methods developed in experimental design, derived from the disciplines of Statistics and Operations Research, are presumed to benefit humanity in general, and not only the individual patient participating in such a formally designed clinical trial. The goals of randomized clinical trials were stated by the Director of the National Institute of Allergy and Infectious Diseases, in these words: “It’s not to deliver therapy. It’s to answer a scientific question so that the drug can be available for everybody once you’ve established safety and efficacy” (as cited in Hellman and Hellman, 1991).

How do randomized clinical trials conflict with a physician’s duty towards his/her individual patients? It is a conflict between rights-based Moral Theories on one hand and Utilitarian Theory on the other.  Moral theories by Immanuel Kant and John Rowls assert that human beings, by virtue of their unique capacity for rational thinking, are bearers of dignity and ought to be treated as ends in themselves not as means to an end. In contrast, Utilitarianism by Stuart Mills defines what is right as the greatest good for the greatest number, known as social utility (Hellman and Hellman, 1991). Pleasures among them, health and well-being, need be counterbalanced by pain. The morally correct act is the act that produces the most pleasure and the least pain overall. Respectively, believers in Moral theory oppose conduct and self participation in randomized clinical trials, while believers in Utilitarianism support them in earnest.

However, since the distribution of pleasure and pain does have moral consequences, physicians must care about that distribution, since they enter into relationships with many patients. They can’t be indifferent to whether it is these patients or others that suffer for the general benefit of society, even though society might gain from the suffering of a few, even if the physician believes that the suffering by a few is worth the benefit to society. The doctor-patient relationship requires doctors to see their patients as bearers of rights who cannot be merely used for the greater good of humanity.

Consider a new agent that promises more effectiveness of treatment. The control group must be given either an unsatisfactory treatment or a placebo. Even though the therapeutic value of the new agent is unproven, if physicians think it has promise, are they acting in the best interest of their patients in allowing them to be randomly assigned to the control group?

Ethical validity of the assignment of patients to randomized clinical trials involves the following three matters in medical ethics (Hellman and Hellman, 1991, Markman, 1992):

  • If the physician has no opinion about whether the new treatment is acceptable, then random assignment is ethically acceptable. Lack of enthusiasm does not lore patients to participate or support the merit of conducting the study anyway. Treatment may show promise of beneficial results but also present undesirable complications (Markman paraphrased)
  • Physician believes that the severity and likelihood of harm and good are evenly balanced, randomization may be ethically acceptable. If the physician has no preference for either treatment, he or she are in a state of equipoise (Freedman, 1992), then randomization is acceptable.
  • If the physician believes that the new treatment may be either more or less successful or more or less toxic, the use of randomization is NOT consistent with fidelity to the patient.

After patient assignment to a Clinical Trial — What are the risks involved in participation in First-In-Man Stent Implantation as a treatment for cardiovascular diseases?

Dr. R. Stack, professor emeritus of medicine at Duke University, Durham, NC, and president of Synecor, a company developing Bioabsorbable stent, traced the evolution of interventional cardiology from inflation of the first angioplasty balloon to implantation of the first Bioabsorbable stent, in a Founders’ Lecture entitled, “How Can You Get Out of a Full-Metal Jacket?” at the Society for Cardiovascular Angiography and Interventions (SCAI), 29th Annual Scientific Sessions in Chicago, May, 2006, and said:

“In the early days of percutaneous transluminal coronary angioplasty (PTCA), each procedure took three to four hours to complete, and fully one in 20 patients suffered a heart attack in the catheterization laboratory. There was little an interventional cardiologist could do, other than rush the patient to surgery. Introduction of the steerable guidewire made PTCA easier to do and shortened procedure times. Development of the perfusion catheter meant that interventional cardiologists could re-establish blood flow to the heart and stabilize patients in case of a sudden arterial blockage. “(cited in David, 2006).

Risks of Participation in Randomized and Non-randomized Clinical Trials: Technology and Procedural Considerations

  • Assignment to a “control group” means implantation of a stent that is gold standard, rather than having the chance of benefiting from an innovative technology such as bioabsorabable stents (Guidant Corporation, 2006) or bioengineered stents (Chadwick, 2006).
  • During the clinical trials manufacturing defects in the device are identified after the device has been implanted in the participants but not in the control group. Wood (2006) reports that: Guidant Corporation has voluntarily stopped enrolling patients in several arms of the nonrandomized portion of its SPIRIT III clinical trial, because one out of every 100 Xience V everolimus-eluting stents may have been manufactured in substandard conditions. The Xience V everolimus-eluting stent received CE Mark approval in 1/2006. Earlier in March 2006, the company announced that it has completed enrollment of 1002 patients in the randomized US portion of the SPIRIT III trial, comparing the Xience V with the TAXUS paclitaxel-eluting stent. Company intents to restock investigators’ supplies and relaunch the trial.
  • Shortcomings of an entire generation of stent technology which is the Gold Standard in major hospitals in US – Drug Eluting Stents (DES)

Drug-eluting stents, introduced just a few years ago, markedly reduce the risk of restenosis. These stents have quickly become a mainstay of interventional therapy, but their use to treat large segments of the coronary circulation has created new challenges. (ABSORB, 2006, Menichelli, 2006, Pfisterer, 2006, Simonton, 2006, Turco, 2006)

Pfisterer, P.E. (2006) at American College of Cardiology 55th Annual ScientificSession, March 11 – 14, 2006, Atlanta, Georgia in his presentation on Basel Stent Cost-Effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trialcompared Drug-eluting stents (DES) with Bare metal stents (BMS) and told the largest audience of interventional cardiologists in the US that

“The results of this small study and the conclusions reached by the authors are certainly a cause for concern. As has been demonstrated by previous studies, the rate of late stent thrombosis after DES implantation was not significantly higher than the rate associated with BMS, but, nevertheless, the consequences are dire. What I find especially troublesome is the fact that we cannot predict with certainty which patients are prone to develop late stent thrombosis and when stent thrombosis is likely to occur — the latter of which is extremely variable in relation to clopidogrel discontinuation. I am not completely convinced that we should advise all patients treated with a DES to continue dual antiplatelet therapy indefinitely, especially when considering high costs and the potential for bleeding complications. This issue generated plenty of debate at the ACC meeting and is far from being resolved” (Pfisterer, 2006).

Does his message have any impact on Cath Labs in US where thousand of drug-eluting stents are stocked and implanted everyday in thousands of cardiovascular patients, and patients with peripheral vascular diseases?

Risk Sources for Complication during Cardiac Catheterization: Patient participation in a randomized or non-randomized Clinical Trial for a new generation of stent devices

  • Clinical – iatrogenic, induced inadvertently by the medical treatment or procedures or activity of a physician
  • Procedural – no change in practice induced, though scientific evidence is available
  • Idiopathic,of the nature of an idiopathy, self originated, of unknown causation.

The first two risk types are addressed, below.

Clinical – iatrogenic, induced inadvertently by the medical treatment or procedures or activity of a physician

  • Access site complications

The most frequently observed complications are related to access site. Such complications, albeit rarely life-threatening, may require additional treatment, including further compression or thrombin injection (for pseudoaneurysms), blood transfusions or vascular surgery. Access site complications may also expose patients to further discomfort, a longer hospital stay and higher hospital costs. For local vascular complications, established predictors are older age, female gender, body surface area, peripheral vascular disease, some antithrombotic regimens and access site (Agostoni, et al. 2006).

  • Expertise level of the physician operator

A recent paper from a non-university hospital showed that expert operators (> 500 procedures performed) had an overall complication rate lower than cardiologists-in-training (despite the fact that it is not clear if they were cardiology fellows or interventional cardiologists-in-training), with a relative risk reduction of approximately 40%, Ammann, et al.(2003). This result is not confirmed by our report. Indeed, fellows, whose maximum caseload is around 300 procedures during the training period, can safely perform cardiac catheterizations, with a complication rate very similar to that of attending physicians. We focused, in particular, on local vascular complications, as arterial puncture is the first procedure step in the training of fellows and usually the only part of the examination they perform alone. An attending physician, who is directly responsible for the whole procedure, supervises the rest. In a recent registry on postcatheterization complications, it was stated: “the involvement of fellows-in-training may have contributed to some complications, especially local” according to Chandrasekar, B., et al.(2001). A study may well complement that report, suggesting the opposite conclusions (Agostoni, et al. 2006).

We report that for Procedural and during Procedure – no change in practice introduced though scientific evidence is available.

  • Extensive use of antithrombotic therapy

The majority of the patients reported in Agostoni, et al.(2006), underwent left heart catheterization because of suspected or known CAD. Thus, they were taking at least one antiplatelet drug despite the fact that it is common practice at our institution to administer a double antiplatelet regimen (aspirin associated with either ticlopidine or clopidogrel) at least 2 days prior to coronary angiography. And for patients with unstable symptoms, they routinely administer subcutaneous unfractionated or low-molecular-weight heparin, which has been shown to significantly increase the risk of local complications. Moreover, in these unstable patients, intravenous heparin was always administered during the procedure, irrespective of the concomitant administration of subcutaneous heparin. Nevertheless, the complication rate in catheterizations performed for reasons other than CAD remained particularly high (3.1%) (Agostoni, et al., 2006).

  • Selection of Access Site

In terms of arterial access site, the radial approach clearly reduced the rate of local complications, with an overall incidence of 0.8% compared to 3.4% after transfemoral catheterizations. A recently published meta-analysis comparing the radial versus the femoral approach for percutaneous coronary diagnostic and interventional procedures, including patients with similar overall characteristics, yielded results comparable to those of the present study. The radial artery approach was electively performed by one senior cardiologist and only occasionally by the others, while cardiology fellows did not perform any transradial procedures (Agostoni, et.al. 2006) [italics added].

If radial artery is implicated with less site access-related complications, why is radial artery used in 30% of the cases, and femoral artery in 70% of percutaneous coronary interventions (PCI)?

  • Additional Risk Factors for Complication during Cardiac Catheterization that are not routinely Checked or Used Peri-procedure.

Percutaneous left heart catheterization, including pressure measurements, left ventriculography, coronary angiography and percutaneous coronary interventions (PCI), is nowadays considered the gold standard for the diagnosis, evaluation and treatment of several cardiac diseases (coronary artery disease [CAD], valvular and congenital heart diseases, cardiomyopathies, status post-heart transplant) (Agostoni, et al. 2006).

Other variables may increase the probability of complication during Cardiac Catheterization.

These intermediate variables are not routinely checked or used.  Thus, they compromise the patient’s chance of achieving the optimal medical results and the best of care. That is after playing the odds of obtaining an assignment in the clinical trial to the “Treatment Group” if a patient was not assigned to either the “Control Group” to be implanted a traditional device or to the “Placebo Group” calling for no device implantation on this round.

Among these variable one finds:

  • antithrombotic regimens other than GP IIb/IIIa inhibitors
  • body surface area calculation
  • identification and consideration of presence of peripheral vascular disease
  • absence of testing for  systematic screening of serum CK-MB levels needed for detection of postprocedural myocardial infarction.
  • absence of cardiac enzymes measurement: before, after, follow up: 2 weeks, 1 month, 6 month, 12 month

Discussion

The first part of the paper deals with the physician’s medical dilemma of assigning patients to randomized clinical trials. The Moral Theory was contrasted with the Utilitarian one. My chosen side/stand on this matter is to identify my values with the Utilitarian group that will participate in randomized clinical trials if medical conditions so require.

In the second part of the paper, I dealt with a realm of risk factors the patient is exposed to after he/she has signed an informed consent and has no longer control. Noteworthy, the risk factors discussed in the paper are not included on any informed consent form. These risks call for modifications to current practices involved in stent implantation technology requiring an immediate consideration.

Two sources of risks were addressed: Clinical and Procedural. These sets of risks are identical for any patient in the Cath Lab, regardless of being assigned to the Treatment Group or to the Control Group. One may not assume that the implantation procedure for a traditional device vs. a new generation device, carries similar risk.  Though the risk of complication during the procedure is very low, when it occurs to someone you care for or to yourself, it is very dire.

Major adverse cardiovascular and cerebrovascular events (MACCE: death, myocardial infarction, cerebrovascular event) were also assessed. The overall access site complication rate was 2.6%. On multivariate regression analysis, the only two predictors of local complications were female gender (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.6–6.5) and femoral approach (OR 3.9, 95% CI 1.2–12.1). The rate of MACCE  (major cardiovascular and cerebrovascular events was 1.2%, mainly after percutaneous coronary interventions, with only 1 death overall (0.07%)(Agostoni, et.al. 2006).

Like most medical ethics issues, there is no single right answer. I would recommend every Cath Lab to revisit every risk factor listed above, discuss them with the Ethics Committee in the Hospital and initiate new procedures to address the clinical and procedural risk factors identified in the context of First-In-Man Stent Implantation.

As other interventional cardiologists, we are looking forward to Generation Five of Stenting Technology that will include the following innovations:

(a) Stents eluding Nitric Oxide (Verma and Marsden, 2005);

(b) stents with coating of an antibody specific (anti-CD34) to the antigen cells that are in the blood, therefore capturing the patient’s circulating endothelial progenitor cells (cEPCs) in order to accelerate the natural healing process (Chadwick, 2006),(Aoki et al., 2005), (Ben-Shoshan & George, 2007), and

(c) EPC-covered intravascular stents deployed for prevention of stent thrombosis and restenosis as well as for rapid formation of normal tissue architecture (Shirota et al., 2003).

Patient safety will be improved if the risk factors identified will raise awareness and will be addressed — preferably, before the next procedure starts in Angiography/Angioplasty Suite #14, ten minutes from now!

According to Rogers & Edelman (2006), “the spectacular success of drug-eluting stents is still plagued by an aura of unease and an insistent drumbeat demanding evidence of success and safety…dramatic reduction in restenosis attended by enhanced rates of thrombosis.” The performance of the two FDA-approved drug-eluting stents (Taxus and Cypher) varies. Cypher is associated with lower restenosis risk. Both devices are pushed into very complex settings to include patients diagnosed with diabetes (different diabetic states may affect restenosis after stenting in different ways). Percutaneous interventions routinely performed in small-vessels, multilesions, diffuse disease, acute coronary syndrome settings and stent-inside-stent as followed up therapy to restenosis. Other failure modes are stent thrombosis, post-procedural myonecrosis, plaque rupture, enhanced disease at a distance and excitation of patients’ already heightened immune state. Other predictors of device failure include lesion type, patient demographics, prior history of coronary bypass surgery, calcification, degree of pre-stent and post-stent stenosis. The variation in performance is critical for patient care decisions and physician’s discrimination between alternative therapies. In most cases the device is selected by the interventional cardiologist with little or no input from the patient.

Research of Clinical/Ethical issues, to emerge in the context of development of clinical trials for First-In-Man Stents, as well as medical ethical issues, to arise during the implantation procedure of the device, and during the period of follow up of the installed base of the device in humans, requires formalization of the data collection and standardization of the statistical analysis procedures. The two leading conferences, where research findings are reported, in the US in 2006 [American College of Cardiology, Annual Scientific Session] and in Europe in 2006 [The European Paris Course on Revascularization (EuroPCR)] are currently presenting challenges for comparative analysis of safety and efficacy.

Development of a schematic rubric, a conceptual proposal for a future study on the “Ethical Medical Issues involved in Clinical Trials for Next Generation Stent Technology.” Implementation of such a study will be most beneficial to all parties involved: physicians, patients, FDA, device manufacturers and medical ethicists. It will involve the following comparative criteria:

  • Medical Ethical Issue
  • Clinical Trial Name
  • Stent Type
  • Number of Patients
  • Major adverse cardiac events
  • Treatment Efficacy
  • Follow up  Studies
  • Clinical Trial Sites
  • Safety of Risk Factors
  • Study Discontinued

REFERENCES

ABSORB (2006). Everolimus Eluting Coronary Stent System First in Man Clinical Investigation. ClinicalTrials.gov Identifier: NCT00300131

Study start: March 2006; Expected completion: June 2011

Last follow-up: March 2011; Data entry closure: May 2011

http://www.clinicaltrials.gov/ct/gui/show/NCT00300131?order=1

Agostoni, P., Anselmi, M., Gasparini, G., Morando, G., Tosi, P., De Benedictis, M.L., Quintarelli, S., Molinari, G., Zardini, P., Turri, M. (2006). Safety of percutaneous left heart catheterization directly performed by cardiology fellows: A cohort analysis. The Journal of Invasive Cardiology, 18 (6), 248-252.

Ammann, P., Brunner-La Rocca H.P., et al. (2003). Procedural complications following diagnostic coronary angiography are related to the operator’s experience and the catheter size. Catheter Cardiovasc Interv , 59, 13–18. 

Aoki, J., Serruys, P.W., van Beusekom, H., Ong, A.T., McFadden, E.P., Sianos, G., et al. (2005). Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 45 (10), 1574–1579.

Ben-Shoshan, J. George, J. (2007). Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: From experimental models to human trials. Pharmacology & Therapeutics, 115, 25-36.

Chadwick , D.(2006) OrbusNeich’s Genous Bioengineered R-stent . Cath Lab Digest, 14 (1), 20-26

Chandrasekar, B., Doucet, S., Bilodeau, L., et al. (2001). Complications of cardiac catheterization in the current era: A single-center experience. Catheter Cardiovasc Interv , 52, 289–295.

David, K.B. (2006). Impressive Progress In Interventional Cardiology – From 1st Balloon Inflation To First Bioabsorbable Stent, Society for Cardiovascular Angiography and Interventions, http://www.scai.org, http://www.medicalnewstoday.com/medicalnews.php?newsid=43313

Freedman, B. (1992). A response to a purported ethical difficulty with randomized clinical trials involving cancer patients.Journal of Clinical Ethics, 3 (3), 231-234.

Guidant Corporation, (2006). Guidant Announces Enrollment of First Patient in Clinical Trial of the World’s First Fully Bioabsorbable Drug Eluting Coronary Stent, 3/9/2006, Source: Guidant Corporation, Indianapolis, IN, www.guidant.com

Hellman, S. and D.S. Hellman (1991). Of mice but not men: Problems of the randomized clinical trial. New England Journal of Medicine, 324 (22), 1589-1592.

Markman, M. (1992). Ethical difficulties with randomized clinical trials involving cancer patients: Examples from the field of gynecologic oncology. Journal of Clinical Ethics, 3 (3), 193-193.

Menichelli, M. (2006). Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial. Presented at The European Paris Course on Revascularization (EuroPCR), May 16-19, 2006, Paris, France Paris, France. http://www.medscape.com/viewprogram/5505?rss

Pfisterer, P.E. (2006). Basel Stent Cost-effectiveness Trial-Late Thrombotic events (BASKET LATE) Trial. Presented at American College of Cardiology 55th Annual Scientific Session, March 11 – 14, 2006, Atlanta, Georgia. http://www.medscape.com/viewprogram/5185 

Rogers, C. Edelman E.R. (2006). Pushing drug-eluting stents into uncharted territory, Simpler then you think – more complex than you imagine. Circulation, 113, 2262-2265.

Shirota, T., Yasui, H., Shimokawa, H. & Matsuda, T. (2003). Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials 24(13), 2295–2302.

Simonton, C. (2006). The STENT Registry: A real-world look at Sirolimus- and Pacitaxel-Eluting Stents. Cath Lab Digest, 14 (1), 1-10.

Turco, M. (2006). TAXUS ATLAS Trial – 9-Month results: Evaluation of TAXUS Liberte vs. TAXUS Express. Presented at The European Paris Course on Revascularization (EuroPCR), May 16-19, 2006, Paris, France Paris, France. http://www.medscape.com/viewprogram/5505?rss

Verma, S. and Marsden, P.A. (2005). Nitric Oxide-Eluting Polyurethanes – Vascular Grafts of the Future? New England Journal Medicine, 353 (7), 730-731.

Wood, S. (2006). Guidant suspends release of Xience V everolimus-eluting stent due to manufacturing standards http://www.theheart.org/article/679851.do 

Read Full Post »

Normality and the Parametric Paradigm

Author and Reporter: Larry H. Bernstein, MD, FCAP

plbern@yahoo.com

This article is about the measure of central tendancy and dispersion of values around the center (mean or median), the underpinning of parametric methods of comparison of 2 or more sets of data.  More importantly, it is the beginning of a statistical journey.  The clinical laboratory deals with large volumes of patient data.  The use of a parametric approach is limited and is prone to problems introduced in the clinical domain.  Consequently, Galen and Gambino introduced the concept of predictive value and the effect of prevalence in a Bayesian context in Beyond Normality. These calculations work off of tables, the same tables that are used for sensitivity and specificity, and are used to calculate a chi squared probability.  The subsequent influence of epidemiology went further in introducing odds and odds ratios.  The third and last article will address the more recent advances beyond, beyond normality.  These improvements have all come about by the development of a powerful statistical methodology that is not constraint by the parametric paradigm and is well developed for hypothesis generation and validation, not just testing of simple hypotheses.

We have grown up with the normal curve and have incorporated it in our thinking, not just our work.  Even the use of the term Six Sigma for reduction of errors has reference to the classical “normal curve” introduced by Johann Carl Friedrich Gauss (1777–1855).  The normal or “bell shaped” curve is a plot of numerical values along the x-axis and the frequency of the occurrence on the y-axis.  If the set of measurements occurs as a random and independent event, we refer to this as parametric, and the distribution of the values is a bell shaped curve with all but 2.5% of the values included within both ends, with the mean or arithmetic average at the center, and with 67% of the sample contained within 1 standard deviation of the mean.   The reference to normality has been used with respect to student test scores, with respect to coin flipping and games of chance, with respect to investment, and in our experience with respect to errors of quality controlled measurements.  The expected value we refer to as the mean (closest to the true value), and the distance from the mean (or scatter) we refer to as dispersion, measured as the standard deviation.  Viewed in this light, we can convert the curve from a standard curve with an actual mean to a standard normal curve with a mean at the center of “0”, and with distances from “0” in standard deviations.   A bad example of this is the distribution of serum AST measurements of a large unselected population enrolled in a clinical trial.  The AST values tend to have many high values, which we call skewness to the right of the curve, so the behavior we are looking for is better described by a log transformation of the values to minimize nonlinearities in the measurement.  This is illustrated by the comparison of AST and log(AST) in Figure 1.

What has not been said is that we view a reference range in terms of a homogeneous population.  This means that while all values might not be the same, the values are scattered within a distance from the mean that becomes less frequent as the distance is larger so that we can describe a mean and a 95% confidence interval around the mean.  In mineralogy we can measure physical elements that have structure defined by a relationship of structure to spectral lines.  Hence, the scatter about the mean is very small because of the precise measurements, even though the quantity may be very small.  This is not necessarily the case with clinical laboratory measurement because of hidden variables, such as – age, diurnal variation, racial factors, and disease.  One way to level the playing field is to compose uniform specimens for quality control that are representative of a population for comparison of laboratory measurements among many laboratories, which is established practice.  What is assumed is that a “normal” population is that population that is found after we remove bias, or contamination of the population by the hidden variable effects mentioned above.  Therefore, parametric statistics is actually a comparison of one or more populations that are to be compared with the hypothetical normal population.   The test of significance is a comparison of A and B with the assumption that they are sampled from the same population, but when they are found to have different means and confidence intervals by a t-test or an analysis of variance, we reject the “null hypothesis” and conclude that they are different based on a p (significance) less than 5%.   There are basic assumptions that are required when we use the parametric paradigm.   The distributions of the samples are the same, normality, the variances are the same, and errors are independent.  Consequently, when comparing 2 samples, as for a placebo and a test drug, these assumptions must hold (which is inherent in the logistic regression).   When we run quality control material, the confidence lines that we use are equivalent to a normal curve turned on its side.  When doing the t-test, the parametric limitations have to be followed.  A result of this is that a minimum of 40 samples are required because as N approaches 40 and over the fit of the data to a normal distribution is more likely.  This is a daily phenomenon in laboratories globally – it takes about 10 – 14 days to be confident about the reference range for a new lot of quality control material, regardless of high, low or normal.  Nevertheless, we have to ask whether we can use a small sample size to validate the reference range of a population sample.  The answer is not so simple.  One can minimize sampling bias by taking a sample of blood donors who are prescreened for serious medical conditions.  The use of laboratory staff donors historically introduced selection bias when the staff was uniformly younger. On the other hand, the amount of computing power readily available to the average practitioner has substantially improved in the last 5 years, and middleware may offer a further opportunity for improvement.  One can download a file with two weeks of results for any test and review and exclude outliers to the established values for the method.  The substantial remaining sample has at least 1,000 patients to work with.  Another method would use a nonparametric adjustment of the data by randomly removing a patient at a time and recalculating. We are not here concerned with distributional assumptions and population parameters. We work only with the data, and we observe the effects of recalculation.   That is an uncommon and unfamiliar approach.

We proceed to the important problem of comparing 2 variables.  Figure 1 is a bivariate plot of data with log(AST) and log(ALT) on each axis.  The result is a scattergram with 95 and 99 percent confidence limits for a reference range formed from two liver tests that meet the parametric constraints.   The scattergram shown in Figure 2 may show correlation, method A and method B, distinctly different, but having a linear association between them.  The parametric assumption holds, and the confidence interval along the so called regression line is determined by ordinary least square regression (OLS).  The subject of regression is a subject worthy of a separate topic.

The next topic is comparing two classes of subjects that we expect to be different because of effects on each group.  This can be represented by the plot of means and standard deviations between patients with ovarian cancer who underwent chemotherapy and either had no or short remission, or had a remission of 20 months, defining treatment success (Figure 2).   The result of means comparison is significant at p < 0.01 using the t-test (Figure 3).   But what if we were to take the same data and compare the patients with no remission, small remission, and complete remission?  One would do the one-way analysis of variance (ANOVA1), which uses the F test (Fisher’s variance ratio).  F is the same as t squared, or t is the square root of F.  The result would again be significant at p < 0.01.

This is a light review of very important methods used in both clinical and research laboratory studies.  They have a history of widespread use going back at least 5 decades, and certainly in experimental physics before biology, although it is from biological observations that we have Fisher’s discriminant function, which gives a linear distance between classified variable, i.e., petal length and petal width.  The discussion to follow will be concerned with tables and the chi squared distribution.

Read Full Post »

« Newer Posts - Older Posts »